0001564590-21-012614 | 10-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 05, 2021	Jun. 30, 2020
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Central Index Key	0001809519
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity File Number	001-39549
Entity Tax Identification Number	47-5104396
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2701 Olympic
Entity Address, Address Line Two	Boulevard
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90404
City Area Code	855
Local Phone Number	268-2822
Trading Symbol	GDRX
Title of 12(b) Security	Class A Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Annual Report	true
Document Transition Report	false
Entity Public Float			$ 0
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement relating to its 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2020 are incorporated herein by reference in Part III.
Class A common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		63,544,290
Class B common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		328,588,785

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 968,691	$ 26,050
Restricted cash	2,900
Accounts receivable, net	68,729	48,129
Prepaid expenses and other current assets	46,048	12,403
Total current assets	1,086,368	86,582
Property and equipment, net	23,057	1,860
Goodwill	261,116	236,225
Intangible assets, net	36,919	21,267
Capitalized software, net	19,800	5,178
Operating lease right-of-use assets	27,712	32,315
Deferred tax assets, net	13,117	2,207
Other assets	2,025	1,162
Total assets	1,470,114	386,796
Current liabilities
Accounts payable	10,291	7,851
Accrued expenses and other current liabilities	37,692	15,556
Current portion of debt	7,029	7,029
Operating lease liabilities, current	4,539	2,937
Total current liabilities	59,551	33,373
Debt, net	659,888	663,893
Operating lease liabilities, net of current portion	33,467	37,129
Other liabilities	5,849	2,974
Total liabilities	758,755	737,369
Commitments and contingencies (Note 13)
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		737,009
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 50,000 and zero shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero shares issued and outstanding at December 31, 2020 and December 31, 2019
Additional paid-in capital	2,101,773	8,788
Accumulated deficit	(1,390,453)	(1,096,830)
Total stockholders' equity (deficit)	711,359	(1,087,582)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	1,470,114	386,796
Common Stock
Stockholders' equity (deficit)
Common stock		460
Total stockholders' equity (deficit)		$ 460
Class A and Class B Common Stock
Stockholders' equity (deficit)
Common stock	39
Total stockholders' equity (deficit)	$ 39

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Redeemable convertible preferred stock, par value	$ 0.006	$ 0.006
Redeemable convertible preferred stock, shares authorized	0	130,000,000
Redeemable convertible preferred stock, shares issued	0	126,046,000
Redeemable convertible preferred stock, shares outstanding	0	126,046,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock
Common stock, par value	$ 0.002	$ 0.002
Common stock, shares authorized	0	380,000,000
Common stock, shares issued	0	229,750,000
Common stock, shares outstanding	0	229,750,000
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	0
Common stock, shares issued	63,071,000	0
Common stock, shares outstanding	63,071,000	0
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	0
Common stock, shares issued	328,589,000	0
Common stock, shares outstanding	328,589,000	0

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 550,700	$ 388,224	$ 249,522
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	29,587	14,016	6,035
Product development and technology	61,816	29,300	43,894
Sales and marketing	255,135	176,967	104,177
General and administrative	461,451	14,692	8,359
Depreciation and amortization	18,430	13,573	9,806
Total costs and operating expenses	826,419	248,548	172,271
Operating (loss) income	(275,719)	139,676	77,251
Other (income) expense:
Other (income) expense, net	(22)	2,967	7
Loss on extinguishment of debt		4,877	2,857
Interest income	(160)	(715)	(154)
Interest expense	27,913	49,569	22,193
Total other expense, net	27,731	56,698	24,903
(Loss) income before income taxes	(303,450)	82,978	52,348
Income tax benefit (expense)	9,827	(16,930)	(8,555)
Net (loss) income	(293,623)	66,048	43,793
Net (loss) income attributable to common stockholders
Basic	(293,623)	42,441	13,795
Diluted	$ (293,623)	$ 42,745	$ 14,226
(Loss) earnings per share:
(Loss) earnings per share - basic	$ (1.07)	$ 0.19	$ 0.12
(Loss) earnings per share - diluted	$ (1.07)	$ 0.18	$ 0.12
Weighted average shares used in computing (loss) earnings per share:
Basic	274,696	226,607	111,842
Diluted	274,696	231,209	118,344
Cost of Sales
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 184	$ 28
Research and Development Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	10,937	1,775	$ 1,048
Selling and Marketing Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	8,789	1,268	544
General and Administrative Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 377,375	$ 676	$ 170

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Initial Public Offering	Private Placement	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock Initial Public Offering	Common Stock	Common Stock Initial Public Offering	Class A and Class B Common Stock	Common Class A Initial Public Offering	Common Class A Private Placement	Common Class B	Additional Paid-in Capital	Additional Paid-in Capital Initial Public Offering	Additional Paid-in Capital Private Placement	Accumulated Deficit
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2017				$ 166,777
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2017				5,654,000
Beginning balance at Dec. 31, 2017	$ (31,753)					$ 157						$ 54,281			$ (86,191)
Beginning balance, Shares at Dec. 31, 2017						78,483,000
Stock options exercised	3,349					$ 11						3,338
Stock options exercised, Shares						5,285,000
Vesting of restricted stock awards, Shares						94,000
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock				$ (166,777)
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock, Shares				(5,654,000)
Conversion of redeemable convertible preferred stock to common stock	166,777					$ 283						166,494
Conversion of redeemable convertible preferred stock to common stock, Shares						141,339,000
Preferred stock issuance, net of issuance costs				$ 737,009
Preferred stock issuance, net of issuance costs, Shares				126,046,000
Stock-based compensation	1,762											1,762
Dividends paid ($152.25 per preferred share, $5.91 per common share)	(1,346,355)											(225,875)			(1,120,480)
Net income (loss)	43,793														43,793
Redeemable convertible preferred stock, Ending balance at Dec. 31, 2018				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2018				126,046,000
Ending balance at Dec. 31, 2018	(1,162,427)					$ 451									(1,162,878)
Ending balance, Shares at Dec. 31, 2018						225,201,000
Stock options exercised	3,042					$ 5						3,037
Stock options exercised, Shares						2,397,000
Issuance of common stock	1,623					$ 1						1,622
Issuance of common stock, Shares						273,000
Restricted stock issuance						$ 3						(3)
Restricted stock issuance, Shares						1,879,000
Stock-based compensation	4,132											4,132
Net income (loss)	66,048														66,048
Redeemable convertible preferred stock, Ending balance at Dec. 31, 2019	$ 737,009			$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2019	126,046,000			126,046,000
Ending balance at Dec. 31, 2019	$ (1,087,582)					$ 460						8,788			(1,096,830)
Ending balance, Shares at Dec. 31, 2019						229,750,000
Stock options exercised	10,831					$ 3						10,828
Stock options exercised, Shares						1,469,000		2,300,000
Vesting of restricted stock awards, Shares								1,252,000
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock					$ (737,009)
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock, Shares					(126,046,000)
Conversion of redeemable convertible preferred stock to common stock		$ 737,009					$ 252						$ 736,757
Conversion of redeemable convertible preferred stock to common stock, Shares							126,046,000
Issuance of common stock		$ 886,856	$ 100,000						$ 3				$ 886,853	$ 100,000
Issuance of common stock, Shares									28,615,000	3,030,000
Stock-based compensation	399,722											399,722
Conversion of common stock into Class B common stock in connection with initial public offering						$ (715)					$ 36	679
Conversion of common stock into Class B common stock in connection with initial public offering, Shares						(357,265,000)					357,265,000
Common stock withheld for tax obligations and net settlement	(83,575)											(83,575)
Common stock withheld for tax obligations and net settlement, Shares								(1,877,000)
Charitable stock donation	41,721											41,721
Charitable stock donation, Shares								1,075,000
Net income (loss)	$ (293,623)														(293,623)
Redeemable convertible preferred stock, Ending balance, Shares at Dec. 31, 2020	0
Ending balance at Dec. 31, 2020	$ 711,359							$ 39				$ 2,101,773			$ (1,390,453)
Ending balance, Shares at Dec. 31, 2020								391,660,000

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2018 $ / shares
Redeemable Convertible Preferred Stock
Dividends paid per preferred share	$ 152.25
Common Stock
Dividends paid per common share	$ 5.91

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net (loss) income	$ (293,623)	$ 66,048	$ 43,793
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	18,430	13,573	9,806
Loss on extinguishment of debt		4,877	2,857
Amortization of debt issuance costs	3,390	3,381	1,239
Non-cash operating lease expense	4,478	2,150
Stock-based compensation	397,285	3,747	1,762
Change in fair value of contingent consideration	2,068
Deferred income taxes	(10,910)	(5,674)	(2,433)
Loss on abandonment and impairment of operating lease assets	961
Charitable stock donation	41,721
Changes in operating assets and liabilities, net of effect of business acquisitions
Accounts receivable	(16,139)	(14,517)	(12,843)
Prepaid expenses and other assets	(40,935)	102	(2,627)
Accounts payable	2,154	515	665
Accrued expenses and other current liabilities	15,010	11,225	77
Operating lease liabilities	4,576	(2,309)
Other liabilities	2,875	168	2,957
Net cash provided by operating activities	131,341	83,286	45,253
Cash flows from investing activities
Purchase of property and equipment	(20,553)	(1,425)	(804)
Acquisitions, net of cash acquired	(55,793)	(31,306)
Capitalized software	(15,271)	(4,324)	(2,654)
Net cash used in investing activities	(91,617)	(37,055)	(3,458)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793
Proceeds from private placement with a related party	100,000
Proceeds from long-term debt	28,000	154,613	901,813
Payments on long-term debt	(35,029)	(211,845)	(294,937)
Payment of debt issuance costs and prepayment penalty	(1,306)	(2,214)	(25,613)
Issuance of preferred stock, net			737,009
Issuance of common stock		1,623
Dividends paid			(1,346,355)
Payments of initial public offering issuance costs	(4,937)
Proceeds from exercise of stock options	5,343	3,042	3,349
Proceeds from early exercise of stock options	667
Employee taxes paid related to net share settlement of equity awards	(78,714)
Net cash provided by (used in) financing activities	905,817	(54,781)	(24,734)
Net change in cash, cash equivalents and restricted cash	945,541	(8,550)	17,061
Cash, cash equivalents and restricted cash
Beginning of year	26,050	34,600	17,539
End of year	971,591	26,050	34,600
Supplemental disclosure of cash flow information
Income taxes	29,228	19,400	11,700
Interest	24,517	48,443	18,658
Non cash investing and financing activities
Purchase of property and equipment included in accounts payable and accrued expenses and other current liabilities	2,100
Right-of-use assets obtained in exchange for new operating lease liabilities	234	29,493
Stock-based compensation included in capitalized software development costs	2,437	385
Capitalized software development costs in accrued expenses and other current liabilities	1,273
Conversion of preferred stock to common stock	737,009		166,777
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets
Cash and cash equivalents	968,691	26,050	34,600
Restricted cash	2,900
End of year	$ 971,591	$ 26,050	$ 34,600

Description of Business

12 Months Ended

Dec. 31, 2020

Description Of Business [Abstract]

Description of Business

1. Description of Business

GoodRx Holdings, Inc. (the “Company”) and its subsidiaries offer information and tools to help consumers compare prices and save on their prescription drug purchases. The Company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States (the “prescription offering”). The services are free to consumers and the Company primarily earns revenue from its core business from Pharmacy Benefit Managers (“PBMs”) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. The Company also offers other healthcare products and services, including telehealth services.

The Company was incorporated in September 2015. On October 7, 2015, the Company acquired 100% of the outstanding shares of GoodRx, Inc. (“GoodRx”). GoodRx was initially formed in September 2011 as GoodRx, Inc., a Delaware corporation.

Initial Public Offering

The Company’s registration statement on Form S-1 (“IPO Registration Statement”) related to its initial public offering (“IPO”) was declared effective on September 22, 2020, and the Company’s Class A common stock began trading on the Nasdaq Global Select Market on September 23, 2020. On September 25, 2020, the Company completed its IPO of 39,807,691 shares of the Company Class A common stock, $0.0001 par value per share (the “Class A Common Stock”) at an offering price of $33.00 per share, pursuant to the Company’s IPO Registration Statement. The Company sold 28,615,034 shares, including 5,192,307 shares that were sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, and certain existing stockholders sold an aggregate of 11,192,657 shares. The Company received aggregate net proceeds of $886.9 million after deducting underwriting discounts and commissions of $52.5 million and other offering expenses of $4.9 million.

Immediately prior to the completion of the IPO, 126,045,531 outstanding shares of redeemable convertible preferred stock with a carrying value of $737.0 million converted into an equivalent number of shares of common stock. Immediately prior to the completion of the IPO, the Company filed an Amended and Restated Certificate of Incorporation, which authorized a total of 2,000,000,000 shares of Class A Common Stock, 1,000,000,000 shares of Class B Common Stock, $0.0001 par value per share, and 50,000,000 shares of Preferred Stock, $0.0001 par value per share (the “Preferred Stock”). Upon the filing of the Amended and Restated Certificate of Incorporation, 357,265,256 shares of the Company’s common stock then outstanding were automatically reclassified into an equivalent number of shares of the Company’s Class B Common Stock. Immediately after the reclassification and prior to the completion of the IPO, a total of 10,098,121 shares of Class B Common Stock held by certain existing shareholders were exchanged for an equivalent number of shares of Class A Common Stock pursuant to terms of certain exchange agreements. As a result, following the completion of the IPO, the Company has two classes of authorized and outstanding common stock: Class A Common Stock and Class B Common Stock.

The rights of the holders of the Class A and Class B Common Stock are identical except for voting and conversion rights. The holders of the Class A Common Stock are entitled to one vote per share and the holders of the Class B Common Stock are entitled to 10 votes per share. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder and will automatically convert to Class A Common Stock upon any transfer, except for certain permitted transfers. All Class B Common Stock will convert automatically into an equivalent number of Class A Common Stock upon the earlier of (i) September 25, 2027; and (ii) the first date the aggregate number of shares of Class B Common Stock cease to represent at least 10% of the aggregate outstanding shares of common stock.

On September 13, 2020, the Company entered into a stock purchase agreement with a related party, that is an existing investor, to issue $100.0 million worth of shares of Class A Common Stock, with the price per share to be equal to the per share price to the public in the Company’s initial public offering of Class A Common Stock. Closing of the investment was subject to certain customary conditions, including the closing of the initial public offering of Class A common stock. Concurrent with the completion of the IPO, the Company issued 3,030,303 shares of Class A Common Stock.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”).

Principles of Consolidation

The consolidated financial statements include the financial statements of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s consolidated financial statements from their respective dates of acquisition.

Consolidation of VIEs

The Company evaluates whether an entity in which it has a variable interest is considered a variable interest entity (“VIE”). VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to make significant decisions through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity).

Under the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation, an entity consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both (a) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance, and (b) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company periodically reassesses whether it is the primary beneficiary of a VIE.

On April 18, 2019, the Company acquired Sappira, Inc. d.b.a. GoodRx Care (formerly known as HeyDoctor). GoodRx Care provides management and other services to Professional Service Corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs.

Total revenue of the VIEs were less than 2% of the Company’s total revenue for the year ended December 31, 2020 and less than 1% of the Company’s total revenue for the period from April 18, 2019 to December 31, 2019. The net results of operations of the VIEs for the years ended December 31, 2020 and 2019 were not material. The VIEs’ total assets and liabilities were each approximately 1% of the Company’s total assets and liabilities at December 31, 2020 and 2019.

Segment Reporting and Geographic Information

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the years ended December 31, 2020, 2019 and 2018, all of the Company’s revenue was from customers located in the United States. In addition, at December 31, 2020 and 2019, all of the Company’s right-of-use assets and property and equipment was in the United States.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the consolidated financial statements include revenue recognition, valuation of intangible assets, and assumptions used for purpose of determining stock-based compensation.

Certain Risks and Concentrations

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with multiple financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts.

The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral.

For the year ended December 31, 2020, three customers accounted for approximately 17%, 14% and 11% of the Company’s revenue. At December 31, 2020, one customer accounted for 12% of the Company’s accounts receivable balance. For the year ended December 31, 2019, two customers accounted for approximately 24% and 23% of the Company’s revenue. At December 31, 2019, two customers accounted for 17% and 16% of the Company’s accounts receivable balance. For the year ended December 31, 2018, three customers accounted for approximately 27%, 19%, and 15% of the Company’s revenue.

In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though beginning in the second half of 2020 activity in the Company’s prescription offering improved. In addition, the Company has experienced a significant increase in demand for the telehealth offerings. The Company only commenced its telehealth offerings following the acquisition of HeyDoctor (now rebranded to GoodRx Care) in April 2019. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making certain judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of December 31, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts, the carrying value of the goodwill and other long-lived assets, incentive-based compensation and income taxes.

As of the date of these consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in the Company’s consolidated financial statements in future periods.

Cash, Cash Equivalents and Restricted Cash

The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted primarily of U.S. Treasury Securities money market funds held with an investment bank and cash on deposit.

Cash equivalents, consisting of money market funds, of $932.5 million and zero at December 31, 2020 and December 31, 2019, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets.

Restricted cash as of December 31, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle business combination relating to contingent consideration.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the amounts due from various customers (primarily PBMs), net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined by management based on historical losses, specific customer circumstances, and general economic conditions. Periodically, management reviews accounts receivable and adjusts the allowance based on circumstances and charges off uncollectible receivables when all attempts to collect have failed. As of December 31, 2020 and 2019, the allowance for doubtful accounts was not material.

Property and Equipment

Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are five years for furniture and fixtures and three years for computer equipment. Leasehold improvements are depreciated on the straight-line basis over the shorter of the life of the asset or the remaining lease term. Expenditures for repairs and maintenance are charged to general and administrative expenses as incurred.

Business Combinations

The results of businesses acquired in a business combination are included in the Company’s consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business being recorded at their estimated fair values on the acquisition date. Any excess consideration over the fair value of assets acquired and liabilities assumed is recognized as goodwill.

The Company performs valuations of assets acquired and liabilities assumed for an acquisition and allocates the purchase price to its respective net tangible and intangible assets. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue, costs, cash flows, discount rates and selection of comparable companies. For material acquisitions, the Company may engage the assistance of valuation specialists in concluding on fair value measurements of certain assets acquired or liabilities assumed in a business combination.

Transaction costs associated with business combinations are expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

Goodwill

Goodwill represents the excess of the consideration transferred and the amount recognized for noncontrolling interest, if any, over the fair value of the identifiable assets acquired and liabilities assumed in a business combination. The Company has one reporting unit during 2020, 2019 and 2018. The Company reviews goodwill for impairment annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. When testing goodwill for impairment, the Company may first perform an optional qualitative assessment. If the Company determines it is not more likely than not the reporting unit’s fair value is less than its carrying value, then no further analysis is necessary. If the Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, then the quantitative impairment test will be performed. Under the quantitative impairment test, if the carrying amount of the Company’s reporting unit exceeds its fair value, the Company will recognize an impairment loss in an amount equal to that excess but limited to the total amount of goodwill. No impairments were recorded in 2020, 2019 and 2018.

Intangible Assets

Intangible assets reflect the value of trademarks, customer relationships, developed technology, and backlog recorded in connection with the Company’s acquisitions. Purchased intangible assets are recorded at their acquisition date fair value, less accumulated amortization. The Company determines the appropriate useful life of intangible assets by performing an analysis of expected cash flows of the acquired assets. Intangible assets are amortized over their estimated useful lives on a straight-line basis, which approximates the pattern in which the economic benefits of the assets are consumed.

Capitalized Software Costs

The Company accounts for its internal-use software costs, including purchased software, in accordance with ASC 350-40, Internal-Use Software. Capitalization of internal-use costs begins when the preliminary project stage is complete, management with the relevant authority authorizes and commits to funding the project, it is probable that the project will be completed, and the software will be used for the function intended. Capitalization of these costs ceases once the project is substantially complete and the software is ready for its intended purpose. Costs incurred for post-configuration training, maintenance and minor modifications or enhancements are expensed to product development and technology costs in the consolidated statements of operations as incurred. Capitalized internal-use costs are amortized on a straight-line basis over their estimated useful life of three years.

Impairment of Long-Lived Assets

The Company accounts for the impairment of long-lived assets in accordance with ASC 360, Impairment or Disposal of Long-Lived Assets. In accordance with ASC 360, long-lived assets to be held and used are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying value. If an asset is determined to be impaired, the impairment is measured by the amount that the carrying value of the asset exceeds its fair value. The Company recognized a loss of $1.0 million in the abandonment and impairment of operating lease assets during the year ended December 31, 2020 related to certain office space that was abandoned or subleased, which is included in general and administrative expenses in the consolidated statement of operations. There was no impairment of long-lived assets identified during the years ended December 31, 2019 and 2018.

Leases

On January 1, 2019, the Company adopted ASC 842, Leases, on a modified retrospective basis, and accordingly, the 2018 consolidated financial statements continue to reflect the application of the previous accounting standard (ASC 840). ASC 842 provided a number of optional practical expedients in transition. The Company elected the “package of practical expedients,” which permitted the Company not to reassess whether a contract is or contains a lease, lease classification and initial direct costs.

The Company has elected to account for lease and non-lease components as a single lease component and also elected not to record operating lease right-of-use assets and operating lease liabilities for leases with an initial term of 12 months or less. Lease payments for short-term leases are recognized as lease expense on a straight-line basis over the lease term.

The Company determines if a contract is, or contains, a lease at inception. All the Company’s leases are operating leases. Leases are included in operating lease right-of-use assets, operating lease liabilities, current and operating lease liabilities, net of current portion on the accompanying consolidated balance sheets. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term discounted using the Company’s incremental borrowing rate. Lease payments include fixed payments and variable payments based on an index or rate, if any, and are recognized as lease expense on a straight-line basis over the term of the lease. The lease term includes options to extend or terminate the lease when it is reasonably certain they will be exercised. As none of the Company’s leases provide an implicit rate, the incremental borrowing rate used is estimated based on what the Company would be required to pay for a collateralized loan over a similar term as the lease. Variable lease payments not based on a rate or index are expensed as incurred.

Debt Issuance Costs

Costs incurred in connection with the issuance of long-term debt are capitalized and amortized to interest expense over the contractual life of the loan using the effective-interest method. These costs are recorded as a reduction of the related long-term debt balance on the accompanying consolidated balance sheets. Costs incurred in connection with the issuance of line of credit facilities are recorded in other assets and are amortized to interest expense on a straight-line basis over the term of the line of credit facility.

Income Taxes

Deferred income tax assets and liabilities are determined based upon the net tax effects of the differences between the Company’s consolidated financial statements carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. A valuation allowance is used to reduce some or all of the deferred tax assets if, based upon the weight of available evidence, it is more likely than not that those deferred tax assets will not be realized.

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties accrued related to its uncertain tax positions in income tax benefit (expense) in the accompanying consolidated statements of operations.

Revenue

The Company’s revenue is primarily derived from prescription transaction fees generated when pharmacies fill prescriptions for consumers. The Company also generates other revenue from subscription, pharmaceutical manufacturer solutions and telehealth services.

On January 1, 2019, the Company adopted ASC 606, Revenue from contracts with customers, on a modified retrospective basis. The adoption of ASC 606 was applied to all contracts at the date of initial application and did not have a material impact on the Company’s revenue recognition. Prior to January 1, 2019, the Company applied ASC 605, Revenue recognition, and recognized revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed and determinable; and (4) collectability is reasonably assured.

Under ASC 606, the Company recognizes revenue when control of the promised good or service is transferred to the customer in an amount that reflects the consideration for which the Company is expected to be entitled to in exchange for those services.

For the years ended December 31, 2020, 2019 and 2018, revenue comprises the following:

	Year Ended December 31,
(in thousands)	2020		2019		2018
Prescription transactions revenue	$	488,257	$	364,582	$	242,911
Other revenue		62,443		23,642		6,611
Total revenue	$	550,700	$	388,224	$	249,522

Prescription Transactions Revenue

Prescription transactions revenue is primarily generated from PBMs, or customers, when a prescription is filled with a GoodRx code provided through the Company’s platform. In its contracts with customers, the nature of the Company’s promise is to direct prescription volume through its platform, which may include marketing through its mobile apps, websites, and GoodRx cards. These activities are not distinct from each other and are not separate performance obligations. The Company’s performance obligation is to connect consumers with pharmacies that are contracted with the Company’s customers. The Company has no performance obligation to fill prescriptions.

Contracts with PBMs provide that the Company is entitled to either a percentage of fees the PBM charges the pharmacy or a fixed amount per type of drug prescription, when a consumer uses a GoodRx code. The Company’s performance obligation is satisfied upon the completion of pharmacies filling prescriptions. The Company recognizes revenues for its estimated fee due from the customers at a point in time when a prescription is filled.

The Company receives reporting from the customers of the number of prescriptions and amount of consideration to which it is entitled at a prescription level. Certain arrangements with PBMs provide that the amount of consideration the Company is entitled to is based on the volume of prescription fills each month. In addition, the amount of consideration for which the Company is entitled may be adjusted in the event that a fill is determined ineligible, or based upon other adjustments allowed under the contracts with customers. The Company estimates the amount it expects to be entitled to using the expected value method based on historical experience of the number of prescriptions filled, ineligible fills and applicable rates.

The Company generally receives payment within 30 days of the month end in which the prescriptions were filled. However, portions of payments may not be received for up to five months to the extent of adjustments for ineligible fills.

Other Revenue

Other revenue consists of subscription revenue, pharmaceutical manufacturer solutions revenue, and telehealth revenue.

Subscription revenue consists of subscriptions to the GoodRx Gold plan (the “Gold plan”) and the Kroger Savings Club powered by GoodRx (the “Kroger plan”). Under the Gold plan, subscribers purchase a monthly subscription that provides access to lower prices for prescriptions and telehealth visits. Subscribers can cancel the Gold subscription at any time. The Company recognizes revenue for the Gold plan over the subscription period. Under the Kroger plan, subscribers pay an annual upfront fee for a subscription that provides access to lower prices on prescriptions at Kroger pharmacies. At the commencement of the subscription term, subscribers pay an annual fee to the Company which the Company shares with Kroger. Kroger plan subscription fees are generally nonrefundable to the subscriber after the first 30 days unless the Company cancels the subscription, in which case the subscriber is entitled to a pro rata refund. The Company recognizes revenue for the Kroger plan over the subscription period, net of the fee shared with Kroger. The amount of deferred revenue recorded related to these plans as of December 31, 2020 and 2019 is $5.3 million and $3.2 million, respectively. Substantially all of the deferred revenue included in the balance sheet at December 31, 2019 was recognized as revenue during 2020 and the Company expects substantially all of the deferred revenue at December 31, 2020 to be recognized as revenue in 2021.

Pharmaceutical manufacturers may purchase advertisements for a fixed fee that appear on the Company’s apps and websites for a specified period of time, and revenue is recognized over the term of the arrangement. Customers may also purchase advertisements where the Company charges fees on a cost-per-click basis or they may purchase advertisements placed in the Company’s direct mailers. Revenue for these arrangements is recognized at a point in time when the advertisement is clicked or when the direct mailer is shipped. The amount of deferred revenue recorded related to these services as of December 31, 2020 and 2019 is $1.5 million and $0.3 million, respectively.

Deferred revenue is included in accrued expenses and other current liabilities in the consolidated balance sheets.

Telehealth revenue consists of revenues generated from consumers who complete a telehealth visit with a member of the Company’s network of qualified medical professionals. Consumers pay a fee per telehealth visit and the Company recognizes the fee as revenue at a point in time when the visit is complete.

Cost of Revenue

Cost of revenue consists primarily of costs related to outsourced consumer support, physician costs for the Company’s telehealth offering, personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for the Company’s consumer support employees, hosting and cloud costs, merchant account fees, and processing fees. Cost of revenue excludes depreciation and amortization of software development costs, developed technology, and other hosting and data infrastructure equipment used to operate the Company’s platforms, which are included in the depreciation and amortization line item in the consolidated statements of operations.

Product Development and Technology

Costs related to the development of products are charged to product development and technology expense as incurred. Product development and technology expense consists primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for employees involved in product development activities, third-party services and contractors related to product development, information technology and software-related costs, and allocated overhead.

Sales and Marketing

Sales and marketing costs consist primarily of advertising and marketing expenses that are expensed as incurred and production costs expensed as of the first date the advertisement takes place. Advertising costs were $222.4 million, $163.7 million and $89.3 million for the years ended December 31, 2020, 2019 and 2018, respectively. The Company does not have any significant minimum advertising or media commitments, other than those disclosed in “Note 13. Commitments and Contingencies”.

Sales and marketing expenses also include personnel costs, including salaries, benefits, bonuses, stock-based compensation expense and sales commissions, for sales and marketing employees, third-party services and contractors, and allocated overhead. Sales commissions relate to contracts with a duration of one year or less and are expensed as incurred.

General and Administrative

General and administrative costs are expensed as incurred and include personnel costs, including salaries, benefits, bonuses and stock-based compensation expense, for executive, finance, accounting, legal, and human resources functions, as well as professional fees, occupancy costs, change in fair value of contingent consideration, charitable donations, and other general overhead costs.

Depreciation and Amortization

The Company’s depreciation and amortization expenses include depreciation of property and equipment, and amortization of capitalized internal-use software costs and intangible assets.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy:

Level 1

Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2

Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs that are derived principally from or corroborated by observable market data by correlation or other means, or inputs other than quoted prices that are observable for the asset or liability; and

Level 3

Unobservable inputs for the asset or liability based on management’s assumptions.

When determining the fair value measurements for assets and liabilities which are required to be measured at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. Goodwill, intangible assets, and other long-lived assets are measured at fair value on a nonrecurring basis, only if impaired. The carrying amounts reported in the consolidated financial statements approximate the fair value for cash equivalents, accounts receivable, accounts payable, and accrued liabilities, due to their short-term nature. The carrying value of the Company’s debt approximates fair value based on the borrowing rate currently available to the Company for financing with similar terms and were determined to be Level 2.

Stock-Based Compensation

Compensation cost is allocated to cost of revenue, product development and technology, sales and marketing, and general and administrative expense in the consolidated statements of operations for stock options, restricted stock awards (“RSAs”), and restricted stock units (“RSUs”) based on the fair value of these awards at the date of grant. For awards that vest based on continued service, stock-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For awards with performance vesting conditions, stock-based compensation cost is recognized on a graded vesting basis over the requisite service period when it is probable the performance condition will be achieved. The grant date fair value of stock options that contain service or performance conditions is estimated using the Black-Scholes option-pricing model and the grant date fair value of RSAs and RSUs that contain service or performance conditions is estimated based on the fair value of the Company’s common stock. For awards with market vesting conditions, the fair value is estimated using a Monte Carlo simulation model that incorporates the likelihood of achieving the market condition. Stock-based compensation cost for awards that contain market vesting conditions is recognized on a graded vesting basis over the requisite service period, even if the market condition is not satisfied. The requisite service period for awards with service, performance and market conditions is the longer of the service period, the performance period or the derived service period from the Monte Carlo simulation model. For awards that contain service, performance and market vesting conditions, the Company commences recognition of stock-based compensation cost once it is probable that the performance condition will be achieved. If the performance condition is an initial public offering or a change in control event, the performance condition is not probable of being achieved for accounting purposes until the event occurs. Once it is probable that the performance condition will be achieved, the Company recognizes stock-based compensation cost over the remaining requisite service period under a graded vesting model, with a cumulative adjustment for the portion of the service period that occurred for the period prior to the performance condition becoming probable of being achieved. Thereafter, expense is recognized even if the market condition was not or is not achieved, provided the employee continues to satisfy the service condition. To the extent that the market vesting conditions are achieved earlier than the end of the requisite service period, then stock-based compensation cost is accelerated. Forfeitures are recognized when they occur.

Determining the fair value of stock-based awards requires judgment. The Black-Scholes option-pricing model is used to estimate the fair value of stock options, while the fair value of the Company’s common stock at the date of grant is used to measure the fair value of RSAs and RSUs. The assumptions used in the Black-Scholes option-pricing model requires the input of subjective assumptions and are as follows:

•

For periods prior to the Company’s IPO, because there was no public market for the Company’s common stock, the fair value of the common stock underlying the Company’s stock-based awards was determined by the Company’s board of directors, with input from management. The Company’s board of directors determined the common stock fair value at the stock option grant date by considering several objective and subjective factors, including the price paid for its common and preferred stock, actual and forecasted operating and financial performance, market conditions and performance of comparable publicly traded companies, developments and milestones within the Company, the rights, preferences, and privileges of its common and preferred stock, and the likelihood of achieving a liquidity event. The fair value for periods prior to the Company’s IPO was determined in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to the Company’s IPO, the fair value of common stock was determined on the grant date using the closing price of the Company’s common stock.

•

Expected volatility is based on historical volatilities of a publicly traded peer group based on daily price observations over a period equivalent to the expected term of the stock option grants.

•

The expected term is based on historical and estimates of future exercise behavior.

•

The risk-free interest rate is based on the U.S. Treasury yield of treasury bonds with a maturity that approximates the expected term of the options.

•

The dividend yield is based on the Company’s current expectations of dividend payouts.

The assumptions used in the Company’s Black-Scholes option-pricing model represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. If factors change and different assumptions are used, the Company’s stock-based compensation could be materially different in the future.

Comprehensive (Loss) Income

During the years ended December 31, 2020, 2019 and 2018, other than net (loss) income, the Company did not have any other elements of comprehensive (loss) income.

Basic and Diluted (Loss) Earnings Per Share

The Company has two classes of common stock, Class A and Class B. Basic and diluted (loss) earnings per share attributable to common stockholders for Class A and Class B common stock were the same because they are entitled to the same liquidation and dividend rights.

The Company computes (loss) earnings per share using the two-class method required for participating securities. The two-class method requires net income to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In periods where the Company has net losses, losses are not allocated to participating securities as they are not required to fund the losses. The Company considers redeemable convertible preferred stock to be participating securities as preferred stockholders have rights to participate in dividends with the common stockholders.

Basic (loss) earnings per share is computed by dividing net (loss) income attributable to common stockholders by the weighted average number of common shares outstanding during the period. Weighted average number of common shares outstanding includes contingently issuable shares where there is no circumstance under which those shares would not be issued. The Co-Chief Executives’ Performance-Vesting Founders Awards (see “Note 15. Stock-Based Compensation”) once vested are settled in shares of common stock on the third anniversary of the applicable vesting date or, if earlier, upon a qualifying change in control event or to satisfy tax withholding requirements. At the time of vesting, these shares are contingently issuable and included in the weighted average number of common shares outstanding for basic (loss) earnings per share.

The Company computes diluted (loss) earnings per share under a two-class method where income is reallocated between common stock, potential common stock and participating securities. Stock-based awards that contain vesting provisions contingent on achievement of performance or market conditions are included in the computation of diluted (loss) earnings per share, if dilutive, from the beginning of the period or date of issuance if later, if all necessary conditions to vest have been satisfied during the period. If all conditions have not been met by the end of the period, dilutive (loss) earnings per share includes the number of shares that would be issuable if the end of the period were the end of the contingency period. Potential common stock includes stock options, RSAs, and RSUs computed using the treasury stock method. For periods where the Company has net losses, diluted (loss) earnings per share is the same as basic (loss) earnings per share, because potentially dilutive shares are excluded from the computation of (loss) earnings per share as their effect is anti-dilutive.

Recent Accounting Pronouncements

As an “emerging growth company,” the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Recently adopted accounting pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. This ASU eliminates, modifies and adds disclosure requirements for fair value measurements. The Company adopted this guidance on January 1, 2020, and the adoption did not have any impact to the consolidated financial statements.

Recently issued accounting pronouncements - not yet adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, to require the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The ASU also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In February 2020, the FASB issued ASU 2020-02, Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), which amends the language in Subtopic 326-20 and addresses questions primarily regarding documentation and company policies. The guidance in ASU 2016-13 and ASU 2020-02 related to credit losses is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. ASU 2018-15 requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud-computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. This guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted. This guidance can be adopted either using the prospective or retrospective transition approach. The Company will adopt this standard on January 1, 2021 and apply the changes prospectively. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements, however it does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities. ASU 2018-17 changes how entities evaluate decision-making fees under the variable interest entity guidance. To determine whether decision-making fees represent a variable interest, an entity considers indirect interests held through related parties under common control on a proportional basis, rather than in their entirety. This guidance is effective for fiscal years, beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, with early adoption permitted. All entities are required to apply the amendments in this ASU retrospectively with a cumulative-effect adjustment to retained earnings at the beginning of the earliest period presented. The Company will adopt this standard on January 1, 2021 and is currently evaluating the impact of this accounting standard update on its consolidated financial statements, however it does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The objective of the guidance is to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and to provide more consistent application to improve the comparability of financial statements. The guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting. The ASU applies only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of the reference rate reform. The amendments in this ASU were effective upon issuance and may be applied through December 31, 2022. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements.

Business Combinations

12 Months Ended

Dec. 31, 2020

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

Scriptcycle, LLC

On August 31, 2020, the Company acquired all of the equity interests of Scriptcycle, LLC, (“Scriptcycle”). Scriptcycle specializes in managing prescription programs and primarily partners with regional retail pharmacy chains to provide discount offerings. The purpose of the acquisition is to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The aggregate purchase consideration was $58.3 million, including the estimated fair value of contingent consideration of $0.8 million. The maximum amount of contingent consideration payable is $2.9 million subject to the achievement of certain revenue thresholds through January 2021. The fair value of the contingent consideration was measured using Level 3 inputs in the fair value hierarchy. The Company estimated the fair value of the acquisition related contingent consideration using a Monte-Carlo simulation model. The Company applied a discount rate of 5.4% at the acquisition date, which captures the risk associated with the contingent consideration. The significant unobservable input used in the fair value measurement of the contingent consideration was forecasted revenue as defined in the purchase agreement.

As of December 31, 2020, the Company estimated the fair value of the contingent consideration to be $2.9 million, which represents the maximum amount of contingent consideration payable, based upon its assessment of the revenue thresholds to be achieved. The change in the fair value of the contingent consideration from the acquisition date through December 31, 2020 is recorded in general and administrative expenses in the accompanying consolidated statement of operations.

Goodwill associated with this acquisition totaled $24.9 million and is primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill is expected to be deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $28.3 million, of which $25.3 million was attributable to a customer related intangible asset, with an estimated useful life of 11 years and $3.0 million was attributable to developed technology and a tradename with useful lives ranging from 1 to 9 years. In addition, the Company acquired current assets of $5.9 million and assumed liabilities of $1.1 million.

Unaudited supplemental pro forma financial information for the Scriptcycle acquisition, and the revenue and earnings of Scriptcycle from the acquisition date through December 31, 2020, have not been presented because the effects were not material to the Company’s consolidated financial statements.

Sappira Inc. (d.b.a GoodRx Care, formerly d.b.a. HeyDoctor)

On April 18, 2019, the Company completed its acquisition of 100% of the equity interests in San Francisco, California-based Sappira Inc. (d.b.a GoodRx Care, formerly d.b.a. as HeyDoctor), a privately-held company offering an online application for consultation with physicians. GoodRx Care can be used by patients to obtain prescriptions for various medical afflictions. The Company uses GoodRx Care’s technology and service offerings to increase the visits to the GoodRx online platform. The total purchase consideration for the acquisition of GoodRx Care was $14.3 million in cash, of which $1.4 million was placed in escrow for potential breaches of representations and warranties. The escrow amount, net of any claims for such indemnifiable matters, was released from escrow to stockholders of GoodRx Care in October 2020.

Goodwill of $9.3 million recorded in connection with this acquisition primarily relating to the expected long-term synergies and other benefits, including the acquired assembled workforce, from the acquisition. The acquisition was considered a stock acquisition for tax purposes and, accordingly, goodwill is not expected to be deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $4.2 million, of which $3.1 million was attributable to developed technology, with an estimated useful life of 4 years and $1.1 million was attributable to trademarks and backlog with useful lives ranging from 1 to 7 years. In addition, the Company acquired current assets of $2.1 million and assumed current liabilities of $0.5 million.

Unaudited supplemental pro forma financial information for the GoodRx Care acquisition, and the revenue and earnings of GoodRx Care from the acquisition date through December 31, 2019, have not been presented because the effects were not material to the Company’s consolidated financial statements.

FocusScript LLC

On August 30, 2019, the Company completed the acquisition of certain software assets and the assembled workforce of Creve Coeur, Missouri-based FocusScript LLC (“FocusScript”). The Company uses the acquired claim routing software to service its customers. The total purchase consideration consisted of $18.7 million in cash.

Goodwill of $6.5 million recorded in connection with this acquisition primarily relating to the expected long-term synergies and other benefits, including the acquired assembled workforce, from the acquisition. Goodwill is deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $12.2 million, which was attributable to developed technology with an estimated useful life of 4 years.

Disclosure of unaudited supplemental pro forma financial information for the FocusScript acquisition is not practicable given the Company purchased certain assets and assembled workforce for which historical information was not available. In addition, disclosure of revenues and earnings of FocusScript from the acquisition date through December 31, 2019 is not practicable as the FocusScript acquisition has been integrated into the Company’s operations.

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2020

Prepaid Expense And Other Assets Current [Abstract]

Prepaid Expenses and Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	December 31,
(in thousands)	2020		2019
Income taxes receivable	$	28,564	$	—
Prepaid expenses		17,484		5,014
Lease incentive receivable		—		7,389
Total prepaid expenses and other current assets	$	46,048	$	12,403

Property and Equipment, Net

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Property and Equipment, Net

5. Property and Equipment, Net

Property and equipment, net consisted of the following:

	December 31,
(in thousands)	2020			2019
Computer equipment	$	2,047		$	1,338
Furniture and fixtures		8,371			556
Leasehold improvements		14,769			1,233
Total property and equipment		25,187			3,127
Less: Accumulated depreciation		(2,130	)		(1,267	)
Total property and equipment, net	$	23,057		$	1,860

For the years ended December 31, 2020, 2019 and 2018, depreciation expense was $1.4 million, $0.7 million and $0.3 million, respectively.

During the fourth quarter of 2020, $21.8 million of capitalized costs, principally comprised of furniture and fixtures and leasehold improvements related to the Company’s new office facility in Santa Monica, California were ready for their intended use and were placed into service.

Goodwill

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill

6. Goodwill

The following table presents changes in the carrying amount of goodwill for the years ended December 31, 2020 and 2019:

	Year Ended December 31,
(in thousands)	2020		2019
Balance at beginning of the year	$	236,225	$	220,420
Add: Sappira Inc. and FocusScript acquisitions		—		15,805
Add: Scriptcycle acquisition		24,891		—
Balance at end of the year	$	261,116	$	236,225

Intangible Assets, Net

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

7. Intangible Assets, Net

The following table presents details of the Company’s intangible assets, net at December 31, 2020:

		December 31, 2020
($ amounts in thousands)	Useful life (years)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trademarks	5-9	$	12,511	$	(11,716	)	$	795
Customer relationships	5-11		27,900		(3,368	)		24,532
Developed technology	1-5		49,098		(37,506	)		11,592
Backlog	1		700		(700	)		—
		$	90,209	$	(53,290	)	$	36,919

The following table presents details of the Company’s intangible assets, net at December 31, 2019:

		December 31, 2019
($ amounts in thousands)	Useful life (years)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trademarks	5-7	$	12,000	$	(9,856	)	$	2,144
Customer relationships	5		2,600		(2,210	)		390
Developed technology	4-5		46,598		(28,075	)		18,523
Backlog	1		700		(490	)		210
		$	61,898	$	(40,631	)	$	21,267

The weighted-average remaining life of intangible assets, net was 8.0 years and 4.4 years at December 31, 2020 and 2019, respectively.

For the years ended December 31, 2020, 2019 and 2018, amortization expense was $12.7 million, $11.2 million and $9.1 million, respectively.

At December 31, 2020, the expected amortization of intangible assets, net for future periods is as follows:

(in thousands)
Year Ending December 31,
2021		7,916
2022		6,240
2023		4,681
2024		2,415
2025		2,413
2026 and thereafter		13,254
	$	36,919

Capitalized Software, Net

12 Months Ended

Dec. 31, 2020

Capitalized Computer Software Net [Abstract]

Capitalized Software, Net

8. Capitalized Software, Net

The following table presents details of the Company’s capitalized software, net as follows:

	December 31,
(in thousands)	2020			2019
Capitalized software costs	$	26,344		$	7,363
Less: Accumulated amortization		(6,544	)		(2,185	)
Total capitalized software, net	$	19,800		$	5,178

For the years ended December 31, 2020, 2019 and 2018, amortization expense was $4.4 million, $1.7 million and $0.4 million, respectively. Amortization has not started on $5.2 million of capitalized software costs that are not yet ready for intended use as of December 31, 2020.

At December 31, 2020, the expected amortization of capitalized software, net that has been placed into service for future periods is as follows:

(in thousands)
Year Ending December 31,
2021	$	6,622
2022		5,272
2023		2,670
	$	14,564

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2020

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

9. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

	December 31,
(in thousands)	2020		2019
Accrued bonus and other payroll related	$	13,607	$	3,037
Accrued marketing		10,045		5,820
Deferred revenue		6,852		3,453
Income taxes payable		—		1,349
Other accrued expenses		7,188		1,897
Total accrued expenses and other current liabilities	$	37,692	$	15,556

Substantially all of the deferred revenue balance included in the balance sheet at December 31, 2019 was recognized as revenue during the year ended December 31, 2020. The Company expects substantially all of the deferred revenue at December 31, 2020 will be recognized as revenue within the next twelve months.

Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Leases

10. Leases

As a result of adopting ASC 842, Leases on January 1, 2019, the Company recorded $4.8 million of operating lease right-of-use assets and $5.2 million of operating lease liabilities on the consolidated balance sheet at January 1, 2019. The difference between the operating lease right-of-use asset and lease liability at the adoption date was deferred rent. The adoption of this guidance had no material impact on the Company’s consolidated statements of operations or consolidated statements of cash flows.

The Company’s leases consist of office facilities under noncancellable operating lease arrangements that expire at various dates through 2031. Certain of the Company’s facility leases contain renewal options for periods of up to 10 years, at the Company’s election. The Company has not recognized any renewal options in its estimate of the lease term as they are not reasonably certain of exercise. None of the Company’s lease agreements contain any material residual value guarantees or material restrictive covenants.

For the years ended December 31, 2020, 2019 and 2018, lease expense of $7.0 million, $3.0 million and $1.9 million, respectively, is included in operating expenses in the consolidated statements of operations. The Company did not have any material variable lease costs or short-term lease expenses for the years ended December 31, 2020, 2019 and 2018. The Company's facility leases do not contain material non-lease components.

Cash paid for amounts affecting the measurement of the Company’s operating lease liabilities included in cash flows from operating activities was $3.0 million (net of $5.7 million of cash collected from lease incentive receivable) and $2.5 million for the years ended December 31, 2020 and 2019, respectively.

As of December 31, 2020 and 2019, the weighted average remaining lease term was 9.2 years and 9.9 years, respectively, and the weighted average discount rate was 6.0% and 5.99%, respectively.

The following table presents maturities of operating lease liabilities at December 31, 2020:

(in thousands)
Year Ending December 31,
2021 ⁽¹⁾	$	4,539
2022		5,343
2023		4,498
2024		4,583
2025		4,760
2026 and thereafter		27,796
Total operating lease payments		51,519
Less: Effects of discounting		(13,513	)
Present value of operating lease liabilities	$	38,006
Operating lease liabilities, current	$	4,539
Operating lease liabilities, net of current portion	$	33,467
⁽¹⁾ net of lease incentives of $1.6 million to be received over the next twelve months.

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

The components of the Company’s income tax (benefit) expense are as follows:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Current
Federal	$	235		$	20,012		$	10,368
State		848			2,592			620
		1,083			22,604			10,988
Deferred
Federal		(7,472	)		(4,670	)		(1,789	)
State		(3,438	)		(1,004	)		(644	)
		(10,910	)		(5,674	)		(2,433	)
Total income tax (benefit) expense	$	(9,827	)	$	16,930		$	8,555

The reconciliation of the income tax (benefit) expense computed at the U.S. Federal statutory rate of 21% to the Company's income tax (benefit) expense is as follows:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Income taxes computed at Federal statutory rate	$	(63,725	)	$	17,425		$	10,993
State income taxes		(2,768	)		988			(154	)
Stock-based compensation		609			313			(99	)
Excess tax benefits related to stock- based compensation		(19,961	)		(788	)		(1,276	)
Research and development credits		(3,541	)		(1,661	)		(858	)
Nondeductible officers' compensation		79,046			—			—
(Decrease) increase in valuation allowance		(293	)		380			—
Other		806			273			(51	)
Income tax (benefit) expense	$	(9,827	)	$	16,930		$	8,555
Effective income tax rate		3.2	%		20.4	%		16.3	%

The components of the net deferred tax assets are as follows:

	December 31,
(in thousands)	2020			2019
Deferred tax assets
Other assets	$	2,303		$	3,108
Lease liabilities		8,747			9,111
Stock-based compensation		4,422			840
Research and development credits, net of reserves		4,146			1,845
Tax credit carryforward		296			—
Charitable contribution carryforward		8,403			—
Goodwill		9,329			2,524
Net operating losses		215			570
Total deferred tax assets		37,861			17,998
Valuation allowance		(268	)		(561	)
Deferred tax assets, net of valuation allowance		37,593			17,437
Deferred tax liabilities
Other liabilities		(825	)		(214	)
Lease assets		(6,377	)		(9,002	)
Property and equipment		(4,621	)		(335	)
Capitalized software		(4,557	)		(1,072	)
Intangible assets		(8,096	)		(4,607	)
Total deferred tax liabilities		(24,476	)		(15,230	)
Net deferred tax assets	$	13,117		$	2,207

The Company regularly reviews its deferred tax assets for recoverability and establishes a valuation allowance when it is more likely that some portion, or all, of the deferred tax assets will not be realized. In making the assessment, the Company is required to consider all available positive and negative evidence to determine whether, based on such evidence, it is more likely than not that some portion or all of the net deferred tax assets will not be realized in future periods. At December 31, 2020, the Company has recorded a valuation allowance of $0.3 million for certain deferred tax assets, primarily related to U.S. net operating loss carryforwards ("NOLs") generated by the Professional Service Corporations (“PSCs”) as sufficient uncertainty exists regarding the future realization of these assets.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law, featuring significant tax provisions and other measures to assist individuals and businesses impacted by the economic effects of the COVID-19 pandemic. The CARES Act increased the Section 163(j) interest expense deduction limitation from 30% to 50% of adjusted taxable income, provided for the payment deferral of certain Social Security taxes, made a technical correction allowing Qualified Improvement Property to be treated as 15-year property, and included numerous other provisions. The CARES Act increased the Company’s interest expense deduction applicable to the 2019 tax year resulting in a reduction of deferred tax assets and a corresponding reduction in income taxes payable of approximately $2.3 million during the quarter ended March 31, 2020.

At December 31, 2020, the Company had U.S. NOLs of $2.9 million available to reduce future federal income taxes. An immaterial portion of these federal NOLs expire in 2037 and the remaining NOLs may be carried over indefinitely. The Company had state NOLs of $1.3 million available to reduce future state income taxes which expire in varying amounts beginning 2029. In 2020, there was a change in ownership of the PSCs. Section 382 of the Internal Revenue Code (“IRC”) limits the utilization of U.S. NOLs following a change of control. As the 2020 change in ownership in the PSCs constitutes a change of control, the Company estimates that approximately $2.2 million of its U.S. NOLs carryforward generated by the PSCs are limited by Section 382. Any adjustment to the estimated Section 382 limitation would not be material to the consolidated financial statements as a full valuation allowance has been established against the NOLs from the PSCs due to uncertainty regarding their future realization.

The Company had California Competes tax credit carryforwards in the amount of $0.4 million available to offset future California income taxes as of December 31, 2020. Under current California law, unused California Competes tax credits may be carried forward for up to six years. At December 31, 2020, the Company also had California research and development tax credit carryforwards in the amount of $7.8 million to offset future California income taxes. Unused California research credits may be carried forward indefinitely. Utilization of these tax credits may be subject to an annual limitation based on changes in ownership, as defined by Section 382/383 of the IRC, as amended.

At December 31, 2020, the tax years 2017 and forward are subject to examination by the IRS, and the tax years 2016 and forward are subject to examination by the various state taxing jurisdictions in which the Company is subject to tax. Currently, income tax audits are occurring in the state of New York and Illinois.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

(in thousands)
Gross unrecognized tax benefits at December 31, 2017	$	865
Increases related to prior year tax positions		458
Increases related to current year tax positions		3,186
Gross unrecognized tax benefits at December 31, 2018		4,509
Decreases related to prior year tax positions		(879	)
Increases related to current year tax positions		744
Gross unrecognized tax benefits at December 31, 2019		4,374
Increases related to prior year tax positions		126
Increases related to current year tax positions		3,327
Settlements with taxing authorities		(119	)
Lapse of statute of limitations		(317	)
Gross unrecognized tax benefits at December 31, 2020	$	7,391

As of December 31, 2020, the Company had unrecognized tax benefits of $7.4 million, $6.7 million of which, if recognized, would impact its effective tax rate.

The Company estimates unrecognized tax benefits will decrease by $0.5 million in 2021 due to the expiration of statute of limitations.

At December 31, 2020 and 2019, accrued interest and penalties related to uncertain tax positions were $0.2 million and $0.1 million, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Debt

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Debt

12. Debt

The Company's debt balances at December 31, 2020 and 2019 were as follows:

	December 31,
(in thousands)	2020			2019
Principal balance under First Lien Credit Agreement	$	681,126		$	688,155
Less: Unamortized debt issuance costs and discounts		(14,209	)		(17,233	)
	$	666,917		$	670,922

First Lien and Second Lien

In October 2018, the Company entered into a First Lien Credit Agreement (“First Lien”) and a Second Lien Credit Agreement (“Second Lien”) with various lenders, for term loans of $545 million and $200 million, respectively. The Second Lien bore interest at a rate equal to the LIBO Screen Rate plus a margin of 7.50% per annum.

In November 2019, the Company entered into an amendment of the First Lien to draw an additional term loan in the amount of $155 million. The additional term loan has the same maturity date and other terms as the original $545 million term loan. The proceeds from the amendment to the First Lien and existing cash resources were used to repay the Second Lien including prepayment penalties. The Company recognized a loss on extinguishment of the Second Lien of $4.9 million from unamortized debt issuance costs and discounts and prepayment penalties. The Company incurred third-party costs related to the amendment of the First Lien of $2.9 million which were expensed as incurred in other expense, net in the consolidated statements of operations.

The First Lien accrues interest at a rate per annum equal to the LIBO Screen Rate plus a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), ranging from 2.75% to 3.00%. The effective interest rate on the First Lien for the years ended December 31, 2020 and 2019 was 3.97% and 5.90%, respectively. The First Lien requires quarterly principal payments from March 2019 through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025. The Company may prepay the First Lien without penalty after April 2019. The First Lien is collateralized by substantially all of the assets of the Company and 100% of the equity interest of GoodRx.

As of December 31, 2020, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At December 31, 2020, the Company was in compliance with its covenants.

The following table presents details of the future principal payments under the debt agreements at December 31, 2020:

(in thousands)
Year Ending December 31,
2021	$	7,029
2022		7,029
2023		7,029
2024		7,029
2025		653,010
Total principal payments	$	681,126

In 2019, the Company incurred debt issuance costs and discounts of $0.6 million relating to the amendment of the First Lien and the issuance the Second Lien. Amortization of debt issuance costs and discounts of $3.0 million, $3.3 million and $0.8 million were recognized as interest expense in the consolidated statements of operations for the years ended December 31, 2020, 2019 and 2018, respectively.

Line of Credit

In October 2018, the Company also obtained a line of credit for up to $40.0 million. During the year ended December 31, 2019, the term of line of credit was extended by one year expiring on October 11, 2024. The line of credit bears interest at a rate equal to the LIBO Screen Rate plus a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), ranging from 2.50 to 3.00% on used amounts and 0.25 to 0.50% on unused amounts. In addition, the line of credit has a fixed fronting fee of 0.125% per annum of the Company’s aggregate undrawn and disbursed but unreimbursed letters of credit. There were no borrowings against the line of credit as of December 31, 2020 and 2019. There were outstanding letters of credit issued against the line of credit for $9.1 million as of December 31, 2020 and 2019, respectively, which reduces the Company’s available borrowings under the line of credit.

In 2019, the Company was required to provide a $9.0 million letter of credit for the benefit of the landlord of a new facility lease which the landlord may draw upon in the event of the Company’s default of rent payment or damages to the building. The letter of credit will decrease by $0.9 million per year commencing in 2023.

In May 2020, GoodRx, Inc., the Company’s wholly owned subsidiary, as borrower, and GoodRx Intermediate Holdings, LLC, entered into an amendment to increase the amount of the line of credit by $60.0 million to a total of $100.0 million. The Company incurred lender and third-party costs of $1.3 million related to the amendment which are recorded in other assets.

The Company borrowed an aggregate of $28.0 million under its line of credit during the year ended December 31, 2020, of which all had been repaid as of December 31, 2020.

Regulatory authorities that oversee financial markets have announced that after the end of 2021, they would no longer compel banks currently reporting information used to set the LIBO Screen Rate to continue to make rate submissions. As a result, it is possible that beginning in 2022, the LIBO Screen Rate will no longer be available as a reference rate. Under the terms of the Company's First Lien Credit Agreement and line of credit, in the event of the discontinuance of the LIBO Screen Rate, a mutually agreed-upon alternate benchmark rate will be established to replace the LIBO Screen Rate. The Company and lenders under its First Lien Credit Agreement and line of credit shall in good faith establish an alternate benchmark rate which places the lenders and the Company in the same economic position that existed immediately prior to the discontinuation of the LIBO Screen Rate. The Company does not anticipate that the discontinuance of the LIBO Screen Rate will materially impact its liquidity or financial position.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

Refer to “Note 10. Leases” and “Note 12. Debt,” for details of contractual obligations for the Company's noncancellable operating leases and principal payments under its debt agreements, respectively.

Contingent Consideration

The Company is subject to a contingent consideration agreement entered into in connection with its acquisition of Scriptcycle, see "Note 3. Business Combinations – Scriptcycle, LLC".

Purchase Commitments

Effective from July 1, 2020, the Company entered into an addendum to its agreement with a third-party, pursuant to which the Company committed to spend an aggregate of $0.6 million in marketing for each of the twelve-month period after July 1, 2020 for the contract duration of three years plus one year of auto renewal. In December 2020, the Company amended its commercial agreement with another third-party, pursuant to which the Company committed to spend an aggregate of at least $3.3 million annually between January 2021 and December 2022 on cloud hosting services.

Legal Contingencies

On December 18, 2020, R. Brian Terenzini, individually and on behalf of all others similarly situated, filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:20-cv-11444). On January 8, 2021, Bryan Kearney, individually and on behalf of all others similarly situated, also filed a class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Central District of California (Case No. 2:21-cv-00175). The plaintiffs seek compensatory damages as well as interest, fees and costs. The complaints allege violations of Section 10(b) of the 1934 Exchange Act, and assert that the Company failed to disclose to investors that Amazon.com, Inc. was developing its own mobile and online prescription medication ordering and fulfillment service that would compete directly with the Company. According to the complaint, when Amazon announced its competitor service, the Company’s stock price fell, causing investor losses. Lead plaintiff applications were due February 16, 2021. Once a lead plaintiff is appointed, the Company intends to file a motion to dismiss. The Company intends to vigorously defend against these claims. The Company believes it has meritorious defenses to the claims of the plaintiff and members of the class and any liability for the alleged claims is not currently probable and a loss or range of loss, if any, is not reasonably estimable.

The pending proceedings described above involve complex questions of fact and law and may require the expenditure of significant funds and the diversion of other resources to defend. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

In addition, during the normal course of business, the Company may become subject to, and is presently involved in, legal proceedings, claims and litigation. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.

The Company does not believe that the disposition of matters that are pending or asserted will have a material effect on its consolidated financial statements.

Indemnifications

The Company’s amended and restated bylaws provides that it will indemnify the Company’s directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. Pursuant to the Company’s indemnification agreements and directors’ and officers’ liability insurance, certain of the Company’s officers and directors will be indemnified and insured against the cost of defense, settlement or payment of a judgment under certain circumstances. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is indeterminable. The Company has never paid a material claim, nor has the Company been involved in litigation, with respect to these indemnification arrangements. As of December 31, 2020 and 2019, the Company has not accrued a liability for these guarantees as, the likelihood of incurring a payment obligation, if any, in connection with these guarantees is not probable or reasonably estimable.

Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

14. Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

The Company previously issued common stock and redeemable convertible preferred stock prior to the IPO. Immediately prior to the completion of the IPO, all outstanding shares of the Company’s common stock and redeemable convertible preferred stock converted into the Company’s Class A and Class B Common Stock (see “Note 1. Description of Business”).

On October 12, 2018, the Company issued 126,045,531 shares of redeemable convertible preferred stock for gross proceeds of $748.8 million. The Company incurred $11.8 million of issuance costs. Concurrent with this investment, all then existing shares of preferred stock (the “old preferred stock”) were converted to common shares.

The holders of old preferred stock were entitled to receive cumulative preferential dividends, if declared, at an annual rate of 10% of the original issue price of each share of preferred stock. In May 2018, the Company used the proceeds from its debt financing and cash on hand to pay cumulative dividends in arrears on the old preferred stock of $18.6 million and also to pay a special dividend to preferred and common stockholders of $154.4 million.

In October 2018, the Company used the proceeds from the First Lien and Second Lien, debt facilities, the proceeds from the issuance of preferred stock, and cash on hand to pay cumulative dividends in arrears on the old preferred stock of $6.4 million immediately prior to their conversion to common stock and to pay special dividends to preferred and common stockholders of approximately $1,167.1 million.

A summary of the significant rights and preferences of the redeemable convertible preferred stock outstanding at December 31, 2019 is as follows:

Conversion

Each share of preferred stock was convertible, at the option of the holder, into shares of common stock by dividing the original issue price by the conversion price, subject to adjustments for certain events as defined by the Amended Certificate of Incorporation. Each redeemable convertible preferred share would automatically be converted into common stock upon the election by the majority of investors provided in writing to the Company at the rate of 1:1. The number of shares of common stock issuable upon conversion of each share of redeemable convertible preferred stock shall be appropriately adjusted to reflect any stock dividend, stock split or other similar event affecting the number of outstanding shares of common stock. Each share of preferred stock would automatically be converted into common stock, (i) immediately prior to the closing of a Qualified IPO, (ii) upon the election of the preferred majority provided in writing to the Company, which notice may be provided at any time, or (iii) immediately at such time as the liquidation preference had been reduced to zero. A Qualified IPO was defined as a sale of any class of shares of the Company, resulting in at least $200 million of net proceeds to the Company, in which the per share price of the shares of Common Stock being offered in such public offering was at least (i) prior to October 12, 2022, 1.25x the original issue price and (ii) on or following October 12, 2022, one times the original issue price. In addition, the Company shall not redeem any portion of the preferred stock, without majority written consent of the preferred stockholders.

Dividends

No dividends would have accrued or been payable with respect to the preferred stock unless declared by the board of directors. In the event a dividend to common stockholders was declared, the Company must also declare and pay to holders of the preferred stock at the same time and in the same amount that the preferred stockholders would have been paid had all outstanding preferred stock been converted immediately prior to the record date for such dividend, or if no record date was fixed, the date as of which record holders of common stock were entitled to such dividends.

Liquidation

In the event of any liquidation, dissolution, winding-up of the Company or deemed liquidation events (as defined), the holders of the preferred stock were entitled to receive for each outstanding share an amount equal to the original issuance price per share plus all declared but unpaid dividends. The original issuance price per share was $5.94. After payment of the liquidation preferences to the preferred stock, all remaining assets were to be distributed to the common stockholders. Any proceeds remaining after payment to the holders of redeemable convertible preferred stock were to be distributed ratably to the holders of common stock.

The liquidation preference provisions of the preferred stock such as a change in control were considered contingent redemption provisions as there were certain elements that were not solely within the control of the Company. Accordingly, the preferred stock was presented in the mezzanine section of the consolidated balance sheet.

Voting

The holders of shares of preferred stock were entitled to vote as a separate class for certain matters. Unless otherwise provided by law or in the current charter, the preferred stockholders voted together with the common stockholders as a single class, on an as converted common stock basis for matters submitted to the stockholders for a vote.

Charitable Stock Donation

In the fourth quarter of 2020, the Company recorded a $41.7 million charge in general and administrative expenses in the accompanying consolidated statement of operations, related to the donation of 1,075,000 shares of Class A Common Stock at fair market value to a charitable organization to fund and support the Company’s philanthropic initiatives. The charitable organization welcomes recommendations from donors regarding distributions from the donations. However, all recommendations are advisory in nature, and the charitable organization will independently determine whether recommendations it receives are consistent with their charitable purposes and fiduciary obligations. The fair value of the donated shares was measured on the date of issuance to the charitable organization using the Company’s traded stock price on that date, and was discounted by 13.0% for a discount for lack of marketability (“DLOM”) as the stock is not freely tradeable. The Company utilized the Finnerty Model to calculate the DLOM using inputs, including length of holding period, volatility and dividend yield, with volatility considered as a significant Level 3 input in the fair value hierarchy.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

15. Stock-Based Compensation

2015 Equity Incentive Plan

The board of directors was authorized to grant stock-based awards under the 2015 Equity Incentive Plan (the “2015 Plan”). Following the effectiveness of the 2020 Plan (as defined below), the 2015 Plan was terminated. However, any outstanding awards granted under the 2015 Plan will remain outstanding, subject to the terms of the 2015 Plan and applicable award agreement. Shares of Class A common stock subject to awards granted under the 2015 Plan that expire unexercised or are cancelled, terminated or forfeited in any manner without issuance of shares thereunder following the effective date of the 2020 Plan, have or will become available for issuance under the 2020 Plan in accordance with its terms.

2020 Incentive Award Plan

In connection with the Company’s IPO in 2020, its board of directors adopted, and its stockholders approved, the 2020 Incentive Award Plan (the “2020 Plan”), which provides for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, RSUs, stock appreciation rights (SARs), and other stock or cash based awards to its employees, consultants and directors, and employees, consultants and directors of its subsidiaries. The board of directors or its Compensation Committee is authorized to grant stock-based awards under the 2020 Plan.

An aggregate of 60.7 million shares of Class A and Class B common stock initially were available for issuance under awards granted pursuant to the 2020 Plan, which shares may be authorized but unissued shares, treasury shares or shares purchased in the open market. Shares may be issued under the 2020 Plan as either Class A or Class B common stock. Notwithstanding anything to the contrary in the 2020 Plan, no more than 300.0 million shares of common stock (either Class A or Class B common stock) may be issued pursuant to the exercise of incentive stock options under the 2020 Plan.

The number of shares available for issuance under the 2020 Plan will be increased by an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 5% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by the Company’s board of directors.

At December 31, 2020, 34.4 million shares were available for issuance under the 2020 Plan.

2020 Employee Stock Purchase Plan

In connection with the Company’s IPO in 2020, its board of directors adopted, and its stockholders approved, the 2020 Employee Stock Purchase Plan (ESPP). A total of 9.0 million shares of Class A common stock were initially reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2021 and ending in 2030, by an amount equal to the lesser of: (i) 1% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company’s board of directors. In no event will more than 100.0 million shares of Class A common stock be available for issuance under the ESPP.

The ESPP allows eligible employees to purchase common stock of the Company, through payroll deductions, at 85% of the lower of the fair market value of Class A common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP is intended to qualify as an employee stock purchase plan under the Internal Revenue Service (“IRS”) Code Section 423. Eligible employees may contribute up to a certain percentage set by the plan administrator of their eligible earnings toward the purchase of the stock (subject to certain IRS limitations). At December 31, 2020, 9.0 million shares were available for issuance under the ESPP.

There were no employee stock purchase offerings during 2020 and accordingly no eligible employees were enrolled in the ESPP during 2020.

Stock Options

Stock options granted generally vest 25% of the total award on the first anniversary of the vesting commencement date, and thereafter ratably monthly over the remaining three-year period. Stock options generally have a ten-year term. Stock options granted under the 2015 Plan and 2020 Plan do not include any forfeitable or non-forfeitable dividend equivalent rights.

A summary of the stock option activity is as follows, in thousands, except per share amounts and term information:

						Weighted
				Weighted		Average
				Average		Remaining	Aggregate
				Exercise		Contractual	Intrinsic
	Shares			Price		Term	Value
Outstanding at December 31, 2019		16,850		$	3.82
Granted		10,019			8.78
Exercised		(3,769	)		2.87
Expired / Cancelled / Forfeited		(1,572	)		4.93
Outstanding at December 31, 2020		21,528		$	6.22	8.1 years	$	734,604
Exercisable at December 31, 2020		9,012		$	3.73	7.1 years	$	329,945

The weighted-average grant date fair value per share of stock options granted for the years ended December 31, 2020, 2019 and 2018 was $4.23, $1.27 and $1.17, respectively. The aggregate intrinsic value of options exercised for the years ended December 31, 2020, 2019 and 2018 was $112.7 million, $11.1 million and $11.2 million, respectively. The fair value of stock options that vested during the years ended December 31, 2020, 2019 and 2018 was $10.2 million, $2.5 million and $1.6 million, respectively.

All stock options outstanding at December 31, 2020 are options to purchase shares of Class A Common Stock. The fair value of option awards issued with service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The following table summarizes the assumptions used:

	Year Ended December 31,
	2020		2019		2018
Risk-free interest rate	0.4% - 1.4%		1.4% - 2.4%		2.7% - 2.9%
Expected term	5.3 - 6.3 years		5.6 - 6.3 years		5.7 - 6.1 years
Expected stock price volatility	50% - 62%		50%		60%
Dividend yield		—		—		—
Fair value of common stock per share	$5.94 - $33.00		$2.75 - $5.88		$1.05 - $2.75

For the years ended December 31, 2020, 2019 and 2018, the stock-based compensation expense related to stock options was $13.0 million, $2.5 million and $1.8 million, respectively. At December 31, 2020, there was $36.8 million of total unrecognized stock-based compensation cost related to stock options, excluding stock options which contain performance and market conditions described below, which is expected to be recognized over a weighted-average remaining service period of 3.0 years.

In June 2020, the Company granted stock options to purchase 0.6 million shares of common stock at an exercise price of $6.84 per share that vest upon continued service and the achievement of both performance and market conditions. For stock options to purchase 0.4 million shares of common stock, the service condition is satisfied monthly over a 4-year period and for stock options to purchase 0.2 million shares of common stock the service condition is satisfied on January 1, 2022. The performance condition is satisfied upon the closing of the Company’s IPO. The market condition is satisfied upon the Company’s common stock achieving a per share price threshold in the IPO, an average trading price of the Company’s stock for a period subsequent to the IPO, or a per share price in a change in control transaction. Both the market and performance conditions were met upon the closing of the Company’s IPO. The Company estimated the grant date fair value of these awards to be $1.4 million using a Monte Carlo simulation model. The Company recognized $0.6 million of stock-based compensation expense in the year ended December 31, 2020 related to these stock options.

In June 2020, the Company modified the terms of a grant to purchase 0.4 million shares of common stock. The original award that would otherwise have been cancelled upon the employee’s departure from the Company was modified to permit the former employee to only exercise the award within 30 days after the completion of a performance condition, which are the Company completing its IPO or a change in control of the Company or a declaration of dividend payment, as defined. The fair value of this stock option of $2.4 million on the modification date was recognized as stock-based compensation expense on the effective date of the Company’s IPO.

Restricted Stock Awards and Restricted Stock Units

A summary of the Restricted Stock Awards and Restricted Stock Unit activity is as follows:

	Restricted			Restricted Stock Units for Class A			Restricted Stock Units for Class B				Weighted Average
	Stock			Common			Common				Grant Date
(in thousands, except per share amounts)	Awards			Stock			Stock				Fair Value
Nonvested restricted stock awards or restricted stock units at December 31, 2019		1,879			—			—			$	3.88
Granted		—			2,800			24,633				23.56
Vested		(470	)		(8	)		(16,935	)	⁽¹⁾		19.26
Forfeited		—			(2	)		—				49.05
Nonvested restricted stock awards or restricted stock units at December 31, 2020		1,409			2,790			7,698			$	26.74
⁽¹⁾ Includes 15,691 of restricted stock units vested but not yet settled related to the Performance-Vesting Founders Awards.

For the year ended December 31, 2020, the fair value of RSAs and RSUs that vested was $335.4 million. The fair value of RSAs that vested during 2019 and 2018 was not material. There were no RSUs granted or outstanding during the years ended December 31, 2019 and 2018.

Restricted Stock Awards

The weighted-average fair value per share of RSAs granted for the year ended December 31, 2019 was $3.88. For the years ended December 31, 2020 and 2019, total stock-based compensation expense related to RSAs was $1.8 million and $1.3 million, respectively. At December 31, 2020, there was $4.2 million of total unrecognized stock-based compensation cost related to these RSAs which is expected to be recognized over the remaining service period of 2.3 years. There were no RSAs granted during the year ended December 31, 2018.

Restricted Stock Units for Class A Common Stock

For the year ended December 31, 2020, the Company granted RSUs for Class A Common Stock. Substantially all of the RSUs granted vest upon continued service over a four-year period. For the year ended December 31, 2020, total stock-based compensation expense related to RSUs was $9.5 million. At December 31, 2020, there was $109.0 million of total unrecognized stock-based compensation cost related to these RSUs which is expected to be recognized over the weighted average remaining service period of 3.7 years.

Restricted Stock Units for Class B Common Stock

On September 11, 2020, the board of directors granted RSUs covering an aggregate of 24,633,066 shares of Class B Common Stock to the Company’s Co-Chief Executive Officers, subject to the completion of the Company’s initial public offering. Each of the Co-Chief Executive Officers received (i) 8,211,022 RSUs that vest based on the achievement of stock price goals ranging from $6.07 per share to $51.28 per share, subject to continued employment through the applicable vesting date (the “Performance-Vesting Founders Awards”) and (ii) 4,105,511 RSUs that vest in equal quarterly installments over four years, subject to continued employment through the applicable vesting date (the “Time-Vesting Founders Awards”). Any Performance-Vesting Founders Awards that vest will be settled in shares of common stock on the third anniversary of the applicable vesting date or, if earlier, upon a qualifying change in control event or to satisfy tax withholding requirements. The Performance-Vesting Founders Awards and Time-Vesting Founders Awards are subject to certain vesting acceleration terms. The grant date fair value of these awards was $533.3 million. The Company used a Monte Carlo simulation model to calculate the grant date fair value of the Performance-Vesting Founders Awards and the derived service period. The Monte Carlo simulation model incorporates the likelihood of achieving the market condition and requires the input of assumptions including the estimated fair value of common stock, expected volatility, expected term, risk-free rate and dividend yield. The primary inputs used in the Monte Carlo simulation model were volatility of 55% and estimated cost of equity of 11%. The Company then applied a 20% DLOM to the value of the RSUs as the issuance of the shares for these awards is deferred by three-years from the applicable vesting date, or earlier, upon a qualifying change in control or to satisfy tax withholding requirements. The Company utilized the Finnerty Model to calculate the DLOM using inputs, including length of holding period, volatility and dividend yield, with volatility considered as a significant Level 3 input in the fair value hierarchy. All the stock price goals with respect to the Performance-Vesting Founders Awards were achieved as of October 22, 2020. As a result, all 16,422,044 Performance-Vesting Founders Awards vested, resulting in recognition of approximately $232.1 million of stock-based compensation expense during the fourth quarter of 2020. The grant date fair value of the Time-Vesting Founders Awards was estimated based on the fair value of the Company's common stock on the date of grant.

As the Performance-Vesting Founders Awards vested in October 2020, the Company settled 0.7 million RSUs during the fourth quarter of 2020, sufficient to satisfy FICA tax withholding obligations due in the year of vesting. The remaining 15.7 million Performance-Vesting Founders Awards shares will not be issued until three years from the vesting date or, if earlier, a change in control event, as defined in the RSU agreements governing the Founders Awards.

During the year ended December 31, 2020, the Company has recognized a cumulative $373.0 million of stock-based compensation expense, with $53.2 million related to the Time-Vesting Founders Awards and $319.8 million related to the Performance-Vesting Founders Awards. At December 31, 2020, there was $160.3 million of total unrecognized stock-based compensation cost related to the Time-Vesting Founders Awards, which is expected to be recognized over the weighted average remaining service period of 2.1 years.

Excess Tax Benefits

The Company recognized excess tax benefits of $21.7 million, $0.9 million and $1.3 million associated with equity award exercises and vesting in its income tax benefit (expense) for the years ended December 31, 2020, 2019 and 2018, respectively.

Tax Withholdings

To meet the related tax withholding requirements for the year ended December 31, 2020, the Company withheld 1.8 million shares of common stock, inclusive of the settlement of 0.7 million RSUs related to the Performance-Vesting Founders Awards, which were returned to the shares reserved for future issuance under the Company’s 2020 Plan. The Company anticipates expending substantial funds to satisfy tax withholding and remittance obligations as the equity awards vest over time.

Bonus Expense for Options

In connection with the dividend payments made to stockholders in May 2018 and October 2018, as further described in “Note 14. Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit),” the Company paid vested option holders cash bonuses totaling $38.8 million which are included in the following components of expenses on the accompanying consolidated statement of operations for the year ended December 31, 2018 as follows:

Cost of revenue	$	—
Product development and technology		29,189
Sales and marketing		6,878
General and administrative		2,733
	$	38,800

The payment of cash bonuses to vested option holders was not required under terms of the options or the 2015 Plan, and did not result in a modification of the stock options.

Basic and Diluted (Loss) Earnings Per Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Basic and Diluted (Loss) Earnings Per Share

16. Basic and Diluted (Loss) Earnings Per Share

The computation of (loss) earnings per share for the years ended December 31, 2020, 2019 and 2018 is as follows:

	Year Ended December 31,
(in thousands, except per share data)	2020			2019			2018
Numerator:
Net (loss) income	$	(293,623	)	$	66,048		$	43,793
Less: Accumulated dividends on convertible preferred stock		—			—			(12,984	)
Less: Undistributed earnings allocated to convertible preferred stock		—			(23,607	)		(17,014	)
Net (loss) income attributable to common stockholders - basic	$	(293,623	)	$	42,441		$	13,795
Add: Undistributed earnings reallocated to holders of common stock		—		304			431
Net (loss) income attributable to common stockholders - diluted	$	(293,623	)	$	42,745		$	14,226
Denominator:
Weighted average shares - basic		274,696			226,607			111,842
Dilutive impact of stock options, restricted stock awards and restricted stock units		—			4,602			6,502
Weighted average shares - diluted		274,696			231,209			118,344
(Loss) earnings per share
Basic	$	(1.07	)	$	0.19		$	0.12
Diluted	$	(1.07	)	$	0.18		$	0.12

The following weighted-average potentially dilutive shares were excluded from the computation of diluted net (loss) earnings per share for the periods presented because including them would have been antidilutive:

	Year Ended December 31,
(in thousands)	2020		2019		2018
Redeemable convertible preferred stock		92,479		126,046		137,946
Stock options, restricted stock awards and restricted stock units		27,374		7,304		2,539

Condensed Financial Information of Parent Company

12 Months Ended

Dec. 31, 2020

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Condensed Financial Information of Parent Company

17. Condensed Financial Information of Parent Company

GoodRx Holdings Inc. has no material assets or standalone operations other than its ownership in its consolidated subsidiaries. Under the terms of debt agreements entered into by GoodRx, a wholly-owned subsidiary of GoodRx Intermediate Holdings, LLC, which itself is a wholly-owned subsidiary of GoodRx Holdings, Inc., GoodRx is restricted from making dividend payments, loans or advances to GoodRx Intermediate Holdings, LLC and GoodRx Holdings, Inc. These restrictions have resulted in the restricted net assets (as defined in Rule 1-02 of Regulation S-X) of GoodRx, Inc. and its subsidiaries to exceed 25% of the consolidated net assets of GoodRx Holdings, Inc. and its subsidiaries.

The condensed financial information is presented on a “parent-only” basis, and GoodRx Holdings Inc.’s investment in its subsidiary is stated at cost plus equity in (loss) earnings of subsidiary less distributions received from subsidiary since the date of the October 7, 2015 acquisition. GoodRx Holdings. Inc.’s share of net (loss) income of its subsidiary is included in net income using the equity method of accounting.

During 2020 and 2019, GoodRx Holdings, Inc. received no dividends from its subsidiary. During 2018, GoodRx Holdings, Inc. received dividends from its subsidiary of $606.0 million.

The following table presents the parent-only balance sheets of GoodRx Holdings, Inc. as of December 31, 2020 and 2019:

	December 31,
(in thousands, except par values)	2020			2019
Assets
Cash	$	5		$	110
Other asset		57			147
Investment in subsidiary, net of distributions		711,384			—
Total assets	$	711,446		$	257
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Investment in subsidiary, net of distributions	$	-		$	350,830
Other current liabilities		87			—
Total liabilities		87			350,830
Redeemable convertible preferred stock
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		—			737,009
Stockholders' equity (deficit)
Common stock, $0.002 par value; zero and 380,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 229,750 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		—			460
Common stock, $0.0001 par value; Class A: 2,000,000 and zero shares authorized, 63,071 and zero shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively; and Class B: 1,000,000 and zero shares authorized, 328,589 and zero shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		39			—
Additional paid-in capital		2,101,773			8,788
Accumulated deficit		(1,390,453	)		(1,096,830	)
Total stockholders' equity (deficit)		711,359			(1,087,582	)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)	$	711,446		$	257

The following table presents the parent-only statements of operations of GoodRx Holdings, Inc. for the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
(in thousands)	2020			2019		2018
Equity in (loss) earnings of subsidiary	$	(293,623	)	$	66,048	$	43,793
Net (loss) income	$	(293,623	)	$	66,048	$	43,793

The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc. for the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Cash flows from operating activities
Net (loss) income	$	(293,623	)	$	66,048		$	43,793
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Equity in loss (earnings) of subsidiary		293,623			(66,048	)		(43,793	)
Changes in assets and liabilities:
Other asset		90			(147	)		—
Other current liabilities		87			—			—
Net cash provided by (used in) operating activities		177			(147	)		—
Cash flows from investing activities
Distribution from subsidiary		—			—			605,997
Investment in subsidiary		(914,434	)		(4,908	)		—
Net cash (used in) provided by investing activities		(914,434	)		(4,908	)		605,997
Cash flows from financing activities
Issuance of preferred stock, net		—			—			737,009
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions		891,793			—			—
Proceeds from private placement with a related party		100,000			—			—
Payments of initial public offering issuance costs		(4,937	)		—			—
Issuance of common stock		—			1,623			—
Dividends paid		—			—			(1,346,355	)
Proceeds from exercise of stock options		5,343			3,042			3,349
Proceeds from early exercise of stock options		667			—			—
Employee taxes paid related to net share settlement of equity awards		(78,714	)		—			—
Net cash provided by (used in) financing activities		914,152			4,665			(605,997	)
Net change in cash		(105	)		(390	)		—
Cash
Beginning of year		110			500			500
End of year	$	5		$	110		$	500

Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

18. Subsequent Events

In March 2021, the Company’s Board of Directors granted RSUs for 0.5 million shares of Class A Common Stock to employees, which will substantially vest over a four-year period. The Company estimates the grant date fair value of these RSUs is approximately $22.8 million, which will be recognized as stock-based compensation cost, net of forfeitures that occur, over approximately four years.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”).

Principles of Consolidation

Consolidation of VIEs

Segment Reporting and Geographic Information

Use of Estimates

Certain Risks and Concentrations

The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral.

Cash, Cash Equivalents and Restricted Cash

Restricted cash as of December 31, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle business combination relating to contingent consideration.

Accounts Receivable and Allowance for Doubtful Accounts

Property and Equipment

Business Combinations

Transaction costs associated with business combinations are expensed as incurred and are included in general and administrative expenses in the consolidated statements of operations.

Goodwill

Intangible Assets

Capitalized Software Costs

Impairment of Long-Lived Assets

For the years ended December 31, 2020, 2019 and 2018, revenue comprises the following:

	Year Ended December 31,
(in thousands)	2020		2019		2018
Prescription transactions revenue	$	488,257	$	364,582	$	242,911
Other revenue		62,443		23,642		6,611
Total revenue	$	550,700	$	388,224	$	249,522

Prescription Transactions Revenue

Other Revenue

Other revenue consists of subscription revenue, pharmaceutical manufacturer solutions revenue, and telehealth revenue.

Deferred revenue is included in accrued expenses and other current liabilities in the consolidated balance sheets.

Cost of Revenue

Product Development and Technology

Sales and Marketing

General and Administrative

Depreciation and Amortization

The Company’s depreciation and amortization expenses include depreciation of property and equipment, and amortization of capitalized internal-use software costs and intangible assets.

Fair Value of Financial Instruments

Level 1

Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2

Level 3

Unobservable inputs for the asset or liability based on management’s assumptions.

Stock-Based Compensation

•

Expected volatility is based on historical volatilities of a publicly traded peer group based on daily price observations over a period equivalent to the expected term of the stock option grants.

•

The expected term is based on historical and estimates of future exercise behavior.

•

The risk-free interest rate is based on the U.S. Treasury yield of treasury bonds with a maturity that approximates the expected term of the options.

•

The dividend yield is based on the Company’s current expectations of dividend payouts.

Comprehensive (Loss) Income

During the years ended December 31, 2020, 2019 and 2018, other than net (loss) income, the Company did not have any other elements of comprehensive (loss) income.

Basic and Diluted (Loss) Earnings Per Share

Recent Accounting Pronouncements

Recently adopted accounting pronouncements

Recently issued accounting pronouncements - not yet adopted

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Revenue

For the years ended December 31, 2020, 2019 and 2018, revenue comprises the following:

	Year Ended December 31,
(in thousands)	2020		2019		2018
Prescription transactions revenue	$	488,257	$	364,582	$	242,911
Other revenue		62,443		23,642		6,611
Total revenue	$	550,700	$	388,224	$	249,522

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2020

Prepaid Expense And Other Assets Current [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	December 31,
(in thousands)	2020		2019
Income taxes receivable	$	28,564	$	—
Prepaid expenses		17,484		5,014
Lease incentive receivable		—		7,389
Total prepaid expenses and other current assets	$	46,048	$	12,403

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2020

Property Plant And Equipment [Abstract]

Schedule of Components of Property and Equipment, Net

Property and equipment, net consisted of the following:

	December 31,
(in thousands)	2020			2019
Computer equipment	$	2,047		$	1,338
Furniture and fixtures		8,371			556
Leasehold improvements		14,769			1,233
Total property and equipment		25,187			3,127
Less: Accumulated depreciation		(2,130	)		(1,267	)
Total property and equipment, net	$	23,057		$	1,860

Goodwill (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Summary of Changes in Carrying Amount of Goodwill

The following table presents changes in the carrying amount of goodwill for the years ended December 31, 2020 and 2019:

	Year Ended December 31,
(in thousands)	2020		2019
Balance at beginning of the year	$	236,225	$	220,420
Add: Sappira Inc. and FocusScript acquisitions		—		15,805
Add: Scriptcycle acquisition		24,891		—
Balance at end of the year	$	261,116	$	236,225

Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

The following table presents details of the Company’s intangible assets, net at December 31, 2020:

		December 31, 2020
($ amounts in thousands)	Useful life (years)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trademarks	5-9	$	12,511	$	(11,716	)	$	795
Customer relationships	5-11		27,900		(3,368	)		24,532
Developed technology	1-5		49,098		(37,506	)		11,592
Backlog	1		700		(700	)		—
		$	90,209	$	(53,290	)	$	36,919

The following table presents details of the Company’s intangible assets, net at December 31, 2019:

		December 31, 2019
($ amounts in thousands)	Useful life (years)	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Trademarks	5-7	$	12,000	$	(9,856	)	$	2,144
Customer relationships	5		2,600		(2,210	)		390
Developed technology	4-5		46,598		(28,075	)		18,523
Backlog	1		700		(490	)		210
		$	61,898	$	(40,631	)	$	21,267

Schedule of Expected Amortization of Intangible Assets, Net for Future Periods

At December 31, 2020, the expected amortization of intangible assets, net for future periods is as follows:

(in thousands)
Year Ending December 31,
2021		7,916
2022		6,240
2023		4,681
2024		2,415
2025		2,413
2026 and thereafter		13,254
	$	36,919

Capitalized Software, Net (Tables)

12 Months Ended

Dec. 31, 2020

Capitalized Computer Software Net [Abstract]

Schedule of Capitalized Software, Net

The following table presents details of the Company’s capitalized software, net as follows:

	December 31,
(in thousands)	2020			2019
Capitalized software costs	$	26,344		$	7,363
Less: Accumulated amortization		(6,544	)		(2,185	)
Total capitalized software, net	$	19,800		$	5,178

Schedule of Expected Amortization of Capitalized Software, Net

At December 31, 2020, the expected amortization of capitalized software, net that has been placed into service for future periods is as follows:

(in thousands)
Year Ending December 31,
2021	$	6,622
2022		5,272
2023		2,670
	$	14,564

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2020

Payables And Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

	December 31,
(in thousands)	2020		2019
Accrued bonus and other payroll related	$	13,607	$	3,037
Accrued marketing		10,045		5,820
Deferred revenue		6,852		3,453
Income taxes payable		—		1,349
Other accrued expenses		7,188		1,897
Total accrued expenses and other current liabilities	$	37,692	$	15,556

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Maturities of Operating Lease Liabilities

The following table presents maturities of operating lease liabilities at December 31, 2020:

(in thousands)
Year Ending December 31,
2021 ⁽¹⁾	$	4,539
2022		5,343
2023		4,498
2024		4,583
2025		4,760
2026 and thereafter		27,796
Total operating lease payments		51,519
Less: Effects of discounting		(13,513	)
Present value of operating lease liabilities	$	38,006
Operating lease liabilities, current	$	4,539
Operating lease liabilities, net of current portion	$	33,467
⁽¹⁾ net of lease incentives of $1.6 million to be received over the next twelve months.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Components of Income tax (Benefit) Expense

The components of the Company’s income tax (benefit) expense are as follows:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Current
Federal	$	235		$	20,012		$	10,368
State		848			2,592			620
		1,083			22,604			10,988
Deferred
Federal		(7,472	)		(4,670	)		(1,789	)
State		(3,438	)		(1,004	)		(644	)
		(10,910	)		(5,674	)		(2,433	)
Total income tax (benefit) expense	$	(9,827	)	$	16,930		$	8,555

Schedule of Reconciliation of Income Tax (Benefit) Expense

The reconciliation of the income tax (benefit) expense computed at the U.S. Federal statutory rate of 21% to the Company's income tax (benefit) expense is as follows:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Income taxes computed at Federal statutory rate	$	(63,725	)	$	17,425		$	10,993
State income taxes		(2,768	)		988			(154	)
Stock-based compensation		609			313			(99	)
Excess tax benefits related to stock- based compensation		(19,961	)		(788	)		(1,276	)
Research and development credits		(3,541	)		(1,661	)		(858	)
Nondeductible officers' compensation		79,046			—			—
(Decrease) increase in valuation allowance		(293	)		380			—
Other		806			273			(51	)
Income tax (benefit) expense	$	(9,827	)	$	16,930		$	8,555
Effective income tax rate		3.2	%		20.4	%		16.3	%

Schedule of Components of Net Deferred Tax Assets

The components of the net deferred tax assets are as follows:

	December 31,
(in thousands)	2020			2019
Deferred tax assets
Other assets	$	2,303		$	3,108
Lease liabilities		8,747			9,111
Stock-based compensation		4,422			840
Research and development credits, net of reserves		4,146			1,845
Tax credit carryforward		296			—
Charitable contribution carryforward		8,403			—
Goodwill		9,329			2,524
Net operating losses		215			570
Total deferred tax assets		37,861			17,998
Valuation allowance		(268	)		(561	)
Deferred tax assets, net of valuation allowance		37,593			17,437
Deferred tax liabilities
Other liabilities		(825	)		(214	)
Lease assets		(6,377	)		(9,002	)
Property and equipment		(4,621	)		(335	)
Capitalized software		(4,557	)		(1,072	)
Intangible assets		(8,096	)		(4,607	)
Total deferred tax liabilities		(24,476	)		(15,230	)
Net deferred tax assets	$	13,117		$	2,207

Schedule of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

(in thousands)
Gross unrecognized tax benefits at December 31, 2017	$	865
Increases related to prior year tax positions		458
Increases related to current year tax positions		3,186
Gross unrecognized tax benefits at December 31, 2018		4,509
Decreases related to prior year tax positions		(879	)
Increases related to current year tax positions		744
Gross unrecognized tax benefits at December 31, 2019		4,374
Increases related to prior year tax positions		126
Increases related to current year tax positions		3,327
Settlements with taxing authorities		(119	)
Lapse of statute of limitations		(317	)
Gross unrecognized tax benefits at December 31, 2020	$	7,391

Debt (Tables)

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Schedule of Debt

The Company's debt balances at December 31, 2020 and 2019 were as follows:

	December 31,
(in thousands)	2020			2019
Principal balance under First Lien Credit Agreement	$	681,126		$	688,155
Less: Unamortized debt issuance costs and discounts		(14,209	)		(17,233	)
	$	666,917		$	670,922

Schedule of Future Principal Payments Under Debt Agreements

The following table presents details of the future principal payments under the debt agreements at December 31, 2020:

(in thousands)
Year Ending December 31,
2021	$	7,029
2022		7,029
2023		7,029
2024		7,029
2025		653,010
Total principal payments	$	681,126

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Stock Option Activity

A summary of the stock option activity is as follows, in thousands, except per share amounts and term information:

						Weighted
				Weighted		Average
				Average		Remaining	Aggregate
				Exercise		Contractual	Intrinsic
	Shares			Price		Term	Value
Outstanding at December 31, 2019		16,850		$	3.82
Granted		10,019			8.78
Exercised		(3,769	)		2.87
Expired / Cancelled / Forfeited		(1,572	)		4.93
Outstanding at December 31, 2020		21,528		$	6.22	8.1 years	$	734,604
Exercisable at December 31, 2020		9,012		$	3.73	7.1 years	$	329,945

Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted

	Year Ended December 31,
	2020		2019		2018
Risk-free interest rate	0.4% - 1.4%		1.4% - 2.4%		2.7% - 2.9%
Expected term	5.3 - 6.3 years		5.6 - 6.3 years		5.7 - 6.1 years
Expected stock price volatility	50% - 62%		50%		60%
Dividend yield		—		—		—
Fair value of common stock per share	$5.94 - $33.00		$2.75 - $5.88		$1.05 - $2.75

Summary of Cash Bonuses Paid to Vested Option Holders Included in Components of Expenses on Accompanying Consolidated Statement of Operations

Cost of revenue	$	—
Product development and technology		29,189
Sales and marketing		6,878
General and administrative		2,733
	$	38,800

Restricted Stock

Summary of Restricted Stock Activity

A summary of the Restricted Stock Awards and Restricted Stock Unit activity is as follows:

	Restricted			Restricted Stock Units for Class A			Restricted Stock Units for Class B				Weighted Average
	Stock			Common			Common				Grant Date
(in thousands, except per share amounts)	Awards			Stock			Stock				Fair Value
Nonvested restricted stock awards or restricted stock units at December 31, 2019		1,879			—			—			$	3.88
Granted		—			2,800			24,633				23.56
Vested		(470	)		(8	)		(16,935	)	⁽¹⁾		19.26
Forfeited		—			(2	)		—				49.05
Nonvested restricted stock awards or restricted stock units at December 31, 2020		1,409			2,790			7,698			$	26.74
⁽¹⁾ Includes 15,691 of restricted stock units vested but not yet settled related to the Performance-Vesting Founders Awards.

Basic and Diluted (Loss) Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule Computation of Earnings (Loss) Per Share

The computation of (loss) earnings per share for the years ended December 31, 2020, 2019 and 2018 is as follows:

	Year Ended December 31,
(in thousands, except per share data)	2020			2019			2018
Numerator:
Net (loss) income	$	(293,623	)	$	66,048		$	43,793
Less: Accumulated dividends on convertible preferred stock		—			—			(12,984	)
Less: Undistributed earnings allocated to convertible preferred stock		—			(23,607	)		(17,014	)
Net (loss) income attributable to common stockholders - basic	$	(293,623	)	$	42,441		$	13,795
Add: Undistributed earnings reallocated to holders of common stock		—		304			431
Net (loss) income attributable to common stockholders - diluted	$	(293,623	)	$	42,745		$	14,226
Denominator:
Weighted average shares - basic		274,696			226,607			111,842
Dilutive impact of stock options, restricted stock awards and restricted stock units		—			4,602			6,502
Weighted average shares - diluted		274,696			231,209			118,344
(Loss) earnings per share
Basic	$	(1.07	)	$	0.19		$	0.12
Diluted	$	(1.07	)	$	0.18		$	0.12

Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share

	Year Ended December 31,
(in thousands)	2020		2019		2018
Redeemable convertible preferred stock		92,479		126,046		137,946
Stock options, restricted stock awards and restricted stock units		27,374		7,304		2,539

Condensed Financial Information of Parent Company (Tables)

12 Months Ended

Dec. 31, 2020

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Schedule of Parent-only Balance Sheets

The following table presents the parent-only balance sheets of GoodRx Holdings, Inc. as of December 31, 2020 and 2019:

	December 31,
(in thousands, except par values)	2020			2019
Assets
Cash	$	5		$	110
Other asset		57			147
Investment in subsidiary, net of distributions		711,384			—
Total assets	$	711,446		$	257
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Investment in subsidiary, net of distributions	$	-		$	350,830
Other current liabilities		87			—
Total liabilities		87			350,830
Redeemable convertible preferred stock
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		—			737,009
Stockholders' equity (deficit)
Common stock, $0.002 par value; zero and 380,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 229,750 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		—			460
Common stock, $0.0001 par value; Class A: 2,000,000 and zero shares authorized, 63,071 and zero shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively; and Class B: 1,000,000 and zero shares authorized, 328,589 and zero shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		39			—
Additional paid-in capital		2,101,773			8,788
Accumulated deficit		(1,390,453	)		(1,096,830	)
Total stockholders' equity (deficit)		711,359			(1,087,582	)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)	$	711,446		$	257

Schedule of Parent-only Statement of Operations

The following table presents the parent-only statements of operations of GoodRx Holdings, Inc. for the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
(in thousands)	2020			2019		2018
Equity in (loss) earnings of subsidiary	$	(293,623	)	$	66,048	$	43,793
Net (loss) income	$	(293,623	)	$	66,048	$	43,793

Schedule of Parent-only Statement of Cash Flows

The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc. for the years ended December 31, 2020, 2019 and 2018:

	Year Ended December 31,
(in thousands)	2020			2019			2018
Cash flows from operating activities
Net (loss) income	$	(293,623	)	$	66,048		$	43,793
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Equity in loss (earnings) of subsidiary		293,623			(66,048	)		(43,793	)
Changes in assets and liabilities:
Other asset		90			(147	)		—
Other current liabilities		87			—			—
Net cash provided by (used in) operating activities		177			(147	)		—
Cash flows from investing activities
Distribution from subsidiary		—			—			605,997
Investment in subsidiary		(914,434	)		(4,908	)		—
Net cash (used in) provided by investing activities		(914,434	)		(4,908	)		605,997
Cash flows from financing activities
Issuance of preferred stock, net		—			—			737,009
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions		891,793			—			—
Proceeds from private placement with a related party		100,000			—			—
Payments of initial public offering issuance costs		(4,937	)		—			—
Issuance of common stock		—			1,623			—
Dividends paid		—			—			(1,346,355	)
Proceeds from exercise of stock options		5,343			3,042			3,349
Proceeds from early exercise of stock options		667			—			—
Employee taxes paid related to net share settlement of equity awards		(78,714	)		—			—
Net cash provided by (used in) financing activities		914,152			4,665			(605,997	)
Net change in cash		(105	)		(390	)		—
Cash
Beginning of year		110			500			500
End of year	$	5		$	110		$	500

Description of Business - Additional Information (Details) - USD ($)			12 Months Ended
	Sep. 25, 2020	Sep. 24, 2020	Dec. 31, 2020	Dec. 31, 2018	Sep. 13, 2020	Dec. 31, 2019	Dec. 31, 2017	Oct. 07, 2015
Description Of Business [Line Items]
Entity incorporation month and year			2015-09
Offering price per share			$ 5.94
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions			$ 891,793,000
Redeemable convertible preferred stock carrying value						$ 737,009,000
Preferred stock, shares authorized		50,000,000	50,000			0
Preferred stock, par value		$ 0.0001	$ 0.0001			$ 0.0001
Percentage of aggregate outstanding shares of common stock to be cease			10.00%
Common stock conversion term			Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder and will automatically convert to Class A Common Stock upon any transfer, except for certain permitted transfers. All Class B Common Stock will convert automatically into an equivalent number of Class A Common Stock upon the earlier of (i) September 25, 2027; and (ii) the first date the aggregate number of shares of Class B Common Stock cease to represent at least 10% of the aggregate outstanding shares of common stock.
Common Class A
Description Of Business [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001			$ 0.0001
Common stock, shares authorized		2,000,000,000	2,000,000,000			0
Conversion of stock, shares converted		10,098,121
Common stock voting rights			one vote per share
Redeemable Convertible Preferred Stock
Description Of Business [Line Items]
Redeemable convertible preferred stock converted into common stock		126,045,531		5,654,000
Redeemable convertible preferred stock carrying value		$ 737,000,000		$ 737,009,000		$ 737,009,000	$ 166,777,000
Common Class B
Description Of Business [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001			$ 0.0001
Common stock, shares authorized		1,000,000,000	1,000,000,000			0
Conversion of stock, shares converted		357,265,256
Common stock voting rights			10 votes per share
Initial Public Offering
Description Of Business [Line Items]
Sale of stock, description of transaction			The Company’s registration statement on Form S-1 (“IPO Registration Statement”) related to its initial public offering (“IPO”) was declared effective on September 22, 2020, and the Company’s Class A common stock began trading on the Nasdaq Global Select Market on September 23, 2020.
Sale of stock, transaction date			Sep. 25, 2020
Number of aggregate shares sold by existing stockholders	11,192,657
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	$ 886,900,000
Underwriting discounts and commissions	52,500,000
Other offering expenses	$ 4,900,000
Initial Public Offering \| Common Class A
Description Of Business [Line Items]
Stock issued during period	39,807,691		28,615,000
Common stock, par value	$ 0.0001
Offering price per share	$ 33.00
Initial Public Offering \| Class A and Class B Common Stock
Description Of Business [Line Items]
Stock issued during period	28,615,034
Initial Public Offering \| Redeemable Convertible Preferred Stock
Description Of Business [Line Items]
Redeemable convertible preferred stock converted into common stock			126,046,000
Underwriters’ Option to Purchase Additional Shares
Description Of Business [Line Items]
Stock issued during period	5,192,307
Private Placement \| Common Class A
Description Of Business [Line Items]
Stock issued during period			3,030,000
Private Placement \| Common Class A \| Related Party
Description Of Business [Line Items]
Stock issued during period	3,030,303
Stock purchase agreement, authorized amount					$ 100,000,000
GoodRx, Inc.
Description Of Business [Line Items]
Percentage of outstanding shares acquired								100.00%

Summary of Significant Accounting Policies - Additional Information (Details)	8 Months Ended	12 Months Ended
	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($) segment ReportingUnit	Dec. 31, 2019 USD ($) segment ReportingUnit	Dec. 31, 2018 USD ($) segment ReportingUnit
Accounting Policies [Line Items]
Variable interest entity's percentage of total assets and liabilities		1.00%	1.00%
Number of operating segments \| segment		1
Property and equipment, depreciation description		Depreciation is computed using the straight-line method over the estimated useful lives of the assets
Number of reporting unit tested for goodwill impairment \| ReportingUnit		1	1	1
Goodwill impairment		$ 0	$ 0	$ 0
Recognized loss of abandonment and impairment of operating lease assets		1,000,000
Impairment of long-lived assets			0	0
Advertising costs		222,400,000	163,700,000	$ 89,300,000
Comprehensive income		$ 0	0
Change in accounting principle accounting standards update adoption date		Jan. 01, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]		true
Change in accounting principle, accounting standards update, adopted [true false]		true
Accounting standards update [Extensible List]		us-gaap:AccountingStandardsUpdate201813Member
Subscription Revenue
Accounting Policies [Line Items]
Deferred revenue	$ 3,200,000	$ 5,300,000	3,200,000
Pharmaceutical Manufacturers Revenue
Accounting Policies [Line Items]
Deferred revenue	300,000	$ 1,500,000	300,000
Capitalized Software Costs
Accounting Policies [Line Items]
Intangible asset, amortization method		amortized on a straight-line basis over their estimated useful life
Intangible asset useful life		3 years
Furniture and Fixtures
Accounting Policies [Line Items]
Useful life of assets		5 years
Computer Equipment
Accounting Policies [Line Items]
Useful life of assets		3 years
Money Market Funds \| Fair Value, Inputs, Level 1
Accounting Policies [Line Items]
Cash equivalents, fair value disclosure	$ 0	$ 932,500,000	$ 0
Customer Concentration Risk \| Revenue From Customer
Accounting Policies [Line Items]
Number of customers \| segment		3	2	3
Customer Concentration Risk \| Revenue From Customer \| Customer One
Accounting Policies [Line Items]
Concentration risk percentage		17.00%	24.00%	27.00%
Customer Concentration Risk \| Revenue From Customer \| Customer Two
Accounting Policies [Line Items]
Concentration risk percentage		14.00%	23.00%	19.00%
Customer Concentration Risk \| Revenue From Customer \| Customer Three
Accounting Policies [Line Items]
Concentration risk percentage		11.00%		15.00%
Credit Concentration Risk \| Accounts Receivable
Accounting Policies [Line Items]
Number of customers \| segment		1	2
Credit Concentration Risk \| Accounts Receivable \| Customer One
Accounting Policies [Line Items]
Concentration risk percentage		12.00%	17.00%
Credit Concentration Risk \| Accounts Receivable \| Customer Two
Accounting Policies [Line Items]
Concentration risk percentage			16.00%
Maximum
Accounting Policies [Line Items]
Variable interest entity's percentage of total revenue	1.00%	2.00%

Summary of Significant Accounting Policies - Summary of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Line Items]
Revenue	$ 550,700	$ 388,224	$ 249,522
Prescription Transactions Revenue
Accounting Policies [Line Items]
Revenue	488,257	364,582	242,911
Other Revenue
Accounting Policies [Line Items]
Revenue	$ 62,443	$ 23,642	$ 6,611

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Business Combinations - Additional Information (Details) $ in Thousands			1 Months Ended	12 Months Ended
	Aug. 30, 2019 USD ($)	Apr. 18, 2019 USD ($)	Aug. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Business Acquisition [Line Items]
Goodwill				$ 261,116	$ 236,225	$ 220,420
Developed Technology \| Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life				1 year	4 years
Developed Technology \| Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life				5 years	5 years
Scriptcycle LLC
Business Acquisition [Line Items]
Date of acquisition			Aug. 31, 2020
Business combination, aggregate consideration			$ 58,300
Estimated fair value of contingent consideration			800
Contingent consideration based on achievement of certain revenue thresholds			2,900	$ 2,900
Goodwill			24,900
Identifiable intangible assets related to acquisition			28,300
Acquired current assets			5,900
Assumed liabilities			1,100
Scriptcycle LLC \| Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 25,300
Identifiable intangible assets estimated useful life			11 years
Scriptcycle LLC \| Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 3,000
Scriptcycle LLC \| Developed Technology and Tradename \| Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			1 year
Scriptcycle LLC \| Developed Technology and Tradename \| Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			9 years
Scriptcycle LLC \| Measurement Input, Discount Rate
Business Acquisition [Line Items]
Business combination consideration discounted rate			5.4
Sappira Inc.
Business Acquisition [Line Items]
Date of acquisition		Apr. 18, 2019
Business combination, aggregate consideration		$ 14,300
Goodwill		9,300
Identifiable intangible assets related to acquisition		4,200
Acquired current assets		2,100
Assumed liabilities		$ 500
Percentage of outstanding shares acquired		100.00%
Consideration placed in escrow for potential breaches		$ 1,400
Sappira Inc. \| Developed Technology
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 3,100
Identifiable intangible assets estimated useful life		4 years
Sappira Inc. \| Trademarks and Backlog
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 1,100
Sappira Inc. \| Trademarks and Backlog \| Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life		1 year
Sappira Inc. \| Trademarks and Backlog \| Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life		7 years
FocusScript LLC
Business Acquisition [Line Items]
Date of acquisition	Aug. 30, 2019
Business combination, aggregate consideration	$ 18,700
FocusScript LLC \| Developed Technology
Business Acquisition [Line Items]
Goodwill	6,500
Identifiable intangible assets related to acquisition	$ 12,200
Identifiable intangible assets estimated useful life	4 years

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Income taxes receivable	$ 28,564
Prepaid expenses	17,484	$ 5,014
Lease incentive receivable	1,600	7,389
Total prepaid expenses and other current assets	$ 46,048	$ 12,403

Property and Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Total property and equipment	$ 25,187	$ 3,127
Less: Accumulated depreciation	(2,130)	(1,267)
Total property and equipment, net	23,057	1,860
Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	2,047	1,338
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	8,371	556
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 14,769	$ 1,233

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 1.4	$ 0.7	$ 0.3
Capitalized costs	$ 21.8

Goodwill - Summary of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Balance at beginning of the year	$ 236,225	$ 220,420
Balance at end of the year	261,116	236,225
Sappira Inc. and FocusScript LLC
Goodwill [Line Items]
Add: acquisitions		$ 15,805
Scriptcycle LLC
Goodwill [Line Items]
Add: acquisitions	$ 24,891

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 90,209	$ 61,898
Accumulated Amortization	(53,290)	(40,631)
Net Carrying Amount	36,919	21,267
Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	12,511	12,000
Accumulated Amortization	(11,716)	(9,856)
Net Carrying Amount	$ 795	$ 2,144
Trademarks \| Minimum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	5 years	5 years
Trademarks \| Maximum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	9 years	7 years
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life		5 years
Gross Carrying Amount	$ 27,900	$ 2,600
Accumulated Amortization	(3,368)	(2,210)
Net Carrying Amount	$ 24,532	390
Customer Relationships \| Minimum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	5 years
Customer Relationships \| Maximum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	11 years
Developed Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 49,098	46,598
Accumulated Amortization	(37,506)	(28,075)
Net Carrying Amount	$ 11,592	$ 18,523
Developed Technology \| Minimum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	1 year	4 years
Developed Technology \| Maximum
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	5 years	5 years
Backlog
Finite Lived Intangible Assets [Line Items]
Intangible asset useful life	1 year	1 year
Gross Carrying Amount	$ 700	$ 700
Accumulated Amortization	$ (700)	(490)
Net Carrying Amount		$ 210

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Weighted-average remaining life of intangible assets	8 years	4 years 4 months 24 days
Amortization expense	$ 12.7	$ 11.2	$ 9.1

Intangible Assets, Net - Schedule of Expected Amortization of Intangible Assets, Net for Future Periods (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
2021	$ 7,916
2022	6,240
2023	4,681
2024	2,415
2025	2,413
2026 and thereafter	13,254
Net Carrying Amount	$ 36,919	$ 21,267

Capitalized Software, Net - Schedule of Capitalized Software, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Capitalized Computer Software Net [Abstract]
Capitalized software costs	$ 26,344	$ 7,363
Less: Accumulated amortization	(6,544)	(2,185)
Total capitalized software, net	$ 19,800	$ 5,178

Capitalized Software, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Capitalized Computer Software Net [Abstract]
Capitalized software, amortization expense	$ 4.4	$ 1.7	$ 0.4
Capitalized software costs not ready for intended use	$ 5.2

Capitalized Software, Net - Schedule of Expected Amortization of Capitalized Software, Net (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Capitalized Computer Software Net [Abstract]
2021	$ 6,622
2022	5,272
2023	2,670
Capitalized computer software, expected amortization, net	$ 14,564

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued bonus and other payroll related	$ 13,607	$ 3,037
Accrued marketing	10,045	5,820
Deferred revenue	6,852	3,453
Income taxes payable		1,349
Other accrued expenses	7,188	1,897
Total accrued expenses and other current liabilities	$ 37,692	$ 15,556

Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 27,712	$ 32,315
Operating lease liabilities, net of current portion	$ 33,467	37,129
Noncancellable operating lease expiry year	2031
Noncancellable operating lease renewal option period	10 years
Noncancellable operating lease option to renewal description	Certain of the Company’s facility leases contain renewal options for periods of up to 10 years, at the Company’s election.
Noncancellable operating lease existence of option to extend	true
Noncancellable operating lease expense	$ 7,000	3,000	$ 1,900
Noncancellable lease, cash paid	3,000	$ 2,500
Noncancellable lease incentive receivable	$ 5,700
Noncancellable operating lease, weighted-average remaining lease term	9 years 2 months 12 days	9 years 10 months 24 days
Noncancellable operating lease, weighted-average discount rate	6.00%	5.99%
ASC-842
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 4,800
Operating lease liabilities, net of current portion	$ 5,200

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Leases [Abstract]

2021

^[1]

$ 4,539

5,343

4,498

4,583

4,760

27,796

Total operating lease payments

51,519

Less: Effects of discounting

(13,513)

Present value of operating lease liabilities

38,006

Operating lease liabilities, current

4,539

$ 2,937

Operating lease liabilities, net of current portion

$ 33,467

$ 37,129

[1]	net of lease incentives of $1.6 million to be received over the next twelve months.

Leases - Schedule of Maturities of Operating Lease Liabilities (Parenthetical) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Lease incentive receivable	$ 1,600	$ 7,389

Income Taxes - Schedule of Components of Income tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current
Federal	$ 235	$ 20,012	$ 10,368
State	848	2,592	620
Current federal and state tax expense (benefit)	1,083	22,604	10,988
Deferred
Federal	(7,472)	(4,670)	(1,789)
State	(3,438)	(1,004)	(644)
Deferred federal and state tax expense (benefit)	(10,910)	(5,674)	(2,433)
Total income tax (benefit) expense	$ (9,827)	$ 16,930	$ 8,555

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended	12 Months Ended
	Mar. 27, 2020	Mar. 26, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Federal statutory rate				21.00%
Deferred tax assets, valuation allowance				$ 268	$ 561
Interest expense deduction percentage of adjusted taxable income, CARES Act	50.00%	30.00%
Reduction in deferred tax assets and income taxes payable, CARES Act			$ 2,300
U.S. NOLs, carryforward				215	570
Unrecognized tax benefits				7,391	4,374	$ 4,509	$ 865
Unrecognized tax benefits that would affect the effective tax rate if recognized				6,700
Decrease in estimated unrecognized tax benefits in 2021 due to expiration of statute of limitations				500
Accrued interest and penalties related to uncertain tax positions				200	$ 100
Federal
Income Taxes [Line Items]
U.S. NOLs				$ 2,900
U.S. NOLS, expiration year				2037
U.S. NOLs, carryforward				$ 2,200
Deferred tax assets, CARES Act				$ 400
Federal \| Maximum
Income Taxes [Line Items]
Deferred tax asset, carryforward period				6 years
State
Income Taxes [Line Items]
State NOLs subject to expire				$ 1,300
State NOLs, expiration beginning year				2029
California Research and Development Credits \| Federal
Income Taxes [Line Items]
Deferred tax assets, CARES Act				$ 7,800

Income Taxes - Schedule of Reconciliation of Income Tax (Benefit) Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes computed at Federal statutory rate	$ (63,725)	$ 17,425	$ 10,993
State income taxes	(2,768)	988	(154)
Stock-based compensation	609	313	(99)
Excess tax benefits related to stock- based compensation	(19,961)	(788)	(1,276)
Research and development credits	(3,541)	(1,661)	(858)
Nondeductible officers' compensation	79,046
(Decrease) increase in valuation allowance	(293)	380
Other	806	273	(51)
Total income tax (benefit) expense	$ (9,827)	$ 16,930	$ 8,555
Effective income tax rate	3.20%	20.40%	16.30%

Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets
Other assets	$ 2,303	$ 3,108
Lease liabilities	8,747	9,111
Stock-based compensation	4,422	840
Research and development credits, net of reserves	4,146	1,845
Tax credit carryforward	296
Charitable contribution carryforward	8,403
Goodwill	9,329	2,524
Net operating losses	215	570
Total deferred tax assets	37,861	17,998
Valuation allowance	(268)	(561)
Deferred tax assets, net of valuation allowance	37,593	17,437
Deferred tax liabilities
Other liabilities	(825)	(214)
Lease assets	(6,377)	(9,002)
Property and equipment	(4,621)	(335)
Capitalized software	(4,557)	(1,072)
Intangible assets	(8,096)	(4,607)
Total deferred tax liabilities	(24,476)	(15,230)
Net deferred tax assets	$ 13,117	$ 2,207

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits	$ 4,374	$ 4,509	$ 865
Increases related to prior year tax positions	126		458
Decreases related to prior year tax positions		(879)
Increases related to current year tax positions	3,327	744	3,186
Settlements with taxing authorities	(119)
Lapse of statue of limitations	(317)
Gross unrecognized tax benefits at December 31, 2018	$ 7,391	$ 4,374	$ 4,509

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total debt	$ 681,126
First Lien Credit Agreement
Debt Instrument [Line Items]
Principal balance	681,126	$ 688,155
Less unamortized debt issuance costs and discounts	(14,209)	(17,233)
Total debt	$ 666,917	$ 670,922

Debt - Additional Information (Details) - USD ($)	1 Months Ended				12 Months Ended
Debt - Additional Information (Details) - USD ($)	May 31, 2020	Dec. 31, 2019	Nov. 30, 2019	Oct. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Line of credit				$ 40,000,000
Loss on extinguishment of debt						$ 4,877,000	$ 2,857,000
Maturity date						Oct. 11, 2024
Debt issuance costs and discounts						$ 600,000
Amortization of debt issuance costs and discounts					$ 3,000,000	$ 3,300,000	$ 800,000
Line of credit facility extended period						1 year
Line of credit fixed fronting fee percentage					0.125%
Principal balance		$ 0			$ 0	$ 0
Decrease of letter of credit		900,000
Increase in line of credit amount	$ 60,000,000
Letter of Credit
Debt Instrument [Line Items]
Principal balance		9,100,000			9,100,000	9,100,000
Letter of Credit \| New Facility Lease
Debt Instrument [Line Items]
Principal balance		$ 9,000,000				$ 9,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from line of credit					28,000,000
Repayments of line of credit					$ 28,000,000
First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit	100,000,000		$ 155,000,000	545,000,000
Effective interest rate		5.90%			3.97%	5.90%
Frequency of interest payment					quarterly
Maturity date					Oct. 10, 2025
Description of payments					The First Lien requires quarterly principal payments from March 2019 through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025.
Covenant terms					As of December 31, 2020, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At December 31, 2020, the Company was in compliance with its covenants.
Maximum net leverage ratio					8.20%
First Lien Credit Agreement \| Other Assets
Debt Instrument [Line Items]
Deferred Finance Costs Net	$ 1,300,000
First Lien Credit Agreement \| GoodRx, Inc.
Debt Instrument [Line Items]
Percentage of collateralized assets					100.00%
First Lien Credit Agreement \| Minimum
Debt Instrument [Line Items]
Interest rate on used amounts					2.75%
Interest rate on used amounts						2.50%
Interest rate on unused amounts						0.25%
First Lien Credit Agreement \| Maximum
Debt Instrument [Line Items]
Interest rate on used amounts					3.00%
Interest rate on used amounts						3.00%
Interest rate on unused amounts						0.50%
First Lien Credit Agreement \| Other Expense, Net
Debt Instrument [Line Items]
Debt third-party costs			2,900,000
Second Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit				$ 200,000,000
Interest rate on used amounts				7.50%
Loss on extinguishment of debt			$ 4,900,000

Debt - Schedule of Future Principal Payments Under Debt Agreements (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Debt Disclosure [Abstract]
2021	$ 7,029
2022	7,029
2023	7,029
2024	7,029
2025	653,010
Total debt	$ 681,126

Commitments and Contingencies - Additional Information (Details) - Purchase Commitment - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Jul. 01, 2020
Purchase Commitment Excluding Longterm Commitment [Line Items]
Aggregate purchase commitment amount committed		$ 0.6
Purchase commitment, description	three years plus one year
Aggregate purchase commitment minimum amount committed	$ 3.3

Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)		1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 12, 2018	Oct. 31, 2018	May 31, 2018	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Preferred stock, shares issued				0	0	0
Issuance costs					$ 4,937,000
Cumulative preferential dividends entitlement as percentage of annual rate of original issue price of each share of preferred stock					10.00%
Cumulative preferred dividends paid in arrears		$ 6,400,000	$ 18,600,000
Offering price per share				$ 5.94	$ 5.94
Charitable stock donation				$ 41,700,000	$ 41,721,000
Percentage of discount rate				13.00%
Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares issued	126,045,531
Gross proceeds from issuance of stock	$ 748,800,000
Issuance costs	$ 11,800,000
Temporary equity into common stock, conversion rate					1
Temporary equity, liquidation preference				$ 0	$ 0
Minimum net proceeds required under qualified initial public offering					$ 200,000,000
Temporary equity, conversion description					Each share of preferred stock was convertible, at the option of the holder, into shares of common stock by dividing the original issue price by the conversion price, subject to adjustments for certain events as defined by the Amended Certificate of Incorporation. Each redeemable convertible preferred share would automatically be converted into common stock upon the election by the majority of investors provided in writing to the Company at the rate of 1:1. The number of shares of common stock issuable upon conversion of each share of redeemable convertible preferred stock shall be appropriately adjusted to reflect any stock dividend, stock split or other similar event affecting the number of outstanding shares of common stock. Each share of preferred stock would automatically be converted into common stock, (i) immediately prior to the closing of a Qualified IPO, (ii) upon the election of the preferred majority provided in writing to the Company, which notice may be provided at any time, or (iii) immediately at such time as the liquidation preference had been reduced to zero. A Qualified IPO was defined as a sale of any class of shares of the Company, resulting in at least $200 million of net proceeds to the Company, in which the per share price of the shares of Common Stock being offered in such public offering was at least (i) prior to October 12, 2022, 1.25x the original issue price and (ii) on or following October 12, 2022, one times the original issue price. In addition, the Company shall not redeem any portion of the preferred stock, without majority written consent of the preferred stockholders.
Temporary equity, dividends accrued or payable					$ 0
Redeemable Convertible Preferred Stock \| Prior To October 12, 2022
Class Of Stock [Line Items]
Offering price per share required under qualified initial public offering as percentage of original issue price					125.00%
Redeemable Convertible Preferred Stock \| On or Following October 12, 2022
Class Of Stock [Line Items]
Offering price per share required under qualified initial public offering as percentage of original issue price					100.00%
Preferred and Common Stockholders
Class Of Stock [Line Items]
Payments of special dividend		$ 1,167,100,000	$ 154,400,000
Common Class A
Class Of Stock [Line Items]
Charitable stock donation, Shares				1,075,000

Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended	12 Months Ended			13 Months Ended
	Sep. 25, 2020 shares	Sep. 11, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2020 USD ($) Employee $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Oct. 31, 2020 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options granted \| $ / shares					$ 4.23	$ 1.27	$ 1.17
Aggregate intrinsic value of options exercised \| $					$ 112,700	$ 11,100	$ 11,200
Fair value of stock options vested \| $					$ 10,200	$ 2,500	$ 1,600
Share based compensation, volatility rate						50.00%	60.00%
Cash bonuses paid to vested option holders \| $							$ 38,800
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares for tax withholding obligations					1,800,000
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercised, Shares					3,769,000
Award vesting percentage					25.00%
Term of stock option					10 years
Stock-based compensation expense \| $					$ 13,000	$ 2,500	$ 1,800
Unrecognized stock-based compensation cost \| $				$ 36,800	$ 36,800
Weighted-average period over which cost is expected to be recognized					3 years
Grant to purchase shares of common stock			400,000
Fair value of stock option \| $			$ 2,400
Weighted average remaining contractual term, Exercisable					7 years 1 month 6 days
Stock Options \| First Anniversary of the Vesting Commencement Date, and Thereafter Ratably Monthly Over the Remaining Period
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					3 years
Performance and Marked Based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $					$ 600
Stock options granted to purchase of common stock			600,000
Exercise price of common stock \| $ / shares			$ 6.84
Estimated grant date fair value \| $			$ 1,400
Performance and Marked Based Stock Options \| Satisfied Monthly Over 4-year
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Stock options granted to purchase of common stock			400,000
Performance and Marked Based Stock Options \| Satisfied on January 1, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			200,000
Stock options vesting date			Jan. 01, 2022
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of RSAs and RSUs vested \| $					$ 335,400
Weighted-average fair value of restricted shares granted \| $ / shares					$ 23.56
Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted						0	0
Restricted shares outstanding						0	0
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $					$ 1,800	$ 1,300
Unrecognized stock-based compensation cost \| $				$ 4,200	$ 4,200
Weighted-average period over which cost is expected to be recognized					2 years 3 months 18 days
Restricted shares granted					0		0
Restricted shares outstanding				1,409,000	1,409,000	1,879,000
Weighted-average fair value of restricted shares granted \| $ / shares						$ 3.88
Shares vested					470,000
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, deferred period					6 years 3 months 18 days	6 years 3 months 18 days	6 years 1 month 6 days
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, deferred period					5 years 3 months 18 days	5 years 7 months 6 days	5 years 8 months 12 days
Common Class A \| Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period					4 years
Stock-based compensation expense \| $					$ 9,500
Weighted-average period over which cost is expected to be recognized					3 years 8 months 12 days
Unrecognized stock-based compensation cost \| $				$ 109,000	$ 109,000
Common Class B \| Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $					373,000
Grant date fair value \| $		$ 533,300
Unrecognized compensation cost \| $				160,300	160,300
Excess tax benefit associated with equity awards \| $					21,700	$ 900	$ 1,300
Common Class B \| Restricted Stock Units ("RSUs") \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted shares granted		24,633,066
Common Class B \| Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $				$ 232,100	$ 319,800
Shares vested				16,422,044
Shares for tax withholding obligations				700,000
Remaining shares not issued until three years from vesting date								15,700,000
Share based compensation, volatility rate		55.00%
Share based compensation, cost of equity		11.00%
Share based compensation, DLOM of issuance of shares		20.00%
Share based compensation, deferred period		3 years
Common Class B \| Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares for tax withholding obligations					700,000
Common Class B \| Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested		8,211,022
Common Class B \| Restricted Stock Units ("RSUs") Time-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense \| $					$ 53,200
Weighted average remaining contractual term, Exercisable					2 years 1 month 6 days
Common Class B \| Restricted Stock Units ("RSUs") Time-Vesting Founders Awards \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Shares vested		4,105,511
Common Class B \| Maximum \| Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price \| $ / shares		$ 51.28
Common Class B \| Minimum \| Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards \| Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price \| $ / shares		$ 6.07
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				34,400,000	34,400,000
2020 Equity Incentive Plan \| Common Class A And Common Class B
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance				60,700,000	60,700,000
Description of shares available for issue					The number of shares available for issuance under the 2020 Plan will be increased by an annual increase on the first day of each calendar year beginning January 1, 2021 and ending on and including January 1, 2030, equal to the lesser of (A) 5% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares as is determined by the Company’s board of directors.
Percentage of shares issued on common stock outstanding					5.00%
2020 Equity Incentive Plan \| Common Class A And Common Class B \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercised, Shares					300,000,000
2020 Employee Stock Purchase Plan \| Common Class A
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance	9,000,000			9,000,000	9,000,000
Description of shares available for issue					In addition, the number of shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2021 and ending in 2030, by an amount equal to the lesser of: (i) 1% of the aggregate number of shares of Class A and Class B common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as is determined by the Company’s board of directors.
Percentage of shares issued on common stock outstanding	1.00%
Purchase price of shares as a percentage of fair market value					85.00%
Employee stock purchase offerings					0
Number of eligible employees enrolled \| Employee					0
2020 Employee Stock Purchase Plan \| Common Class A \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares available for issuance	100,000,000

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate Intrinsic Value, Exercised	$ 112,700	$ 11,100	$ 11,200
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding, Beginning balance	16,850
Granted, shares	10,019
Exercised, shares	(3,769)
Expired / Cancelled / Forfeited, shares	(1,572)
Shares outstanding, Ending Balance	21,528	16,850
Exercisable at December 31, 2020	9,012
Weighted Average Exercise Prices, Beginning balance	$ 3.82
Weighted Average Exercise Prices, granted	8.78
Weighted Average Exercise Prices, Exercised	2.87
Weighted Average Exercise Prices, Expired/ Cancelled/ Forfeited	4.93
Weighted Average Exercise Prices, Ending balance	6.22	$ 3.82
Weighted Average Exercise Prices, Exercisable at December 31, 2020	$ 3.73
Weighted average remaining contractual term, Outstanding	8 years 1 month 6 days
Weighted average remaining contractual term, Exercisable	7 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 734,604
Aggregate Intrinsic Value, Exercisable	$ 329,945

Stock-Based Compensation - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.40%	1.40%	2.70%
Risk-free interest rate, maximum	1.40%	2.40%	2.90%
Expected stock price volatility		50.00%	60.00%
Expected stock price volatility, minimum	50.00%
Expected stock price volatility, maximum	62.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 3 months 18 days	5 years 7 months 6 days	5 years 8 months 12 days
Fair value of common stock per share	$ 5.94	$ 2.75	$ 1.05
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 3 months 18 days	6 years 3 months 18 days	6 years 1 month 6 days
Fair value of common stock per share	$ 33.00	$ 5.88	$ 2.75

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	1,879,000
Granted	0		0
Vested	(470,000)
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	1,409,000	1,879,000
Granted, Weighted Average Grant Date Fair Value		$ 3.88
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	0
Granted	2,800,000
Vested	(8,000)
Forfeited	(2,000)
Nonvested restricted stock awards or restricted stock units, Ending Balance	2,790,000	0
Restricted Stock Units for Class B Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Beginning Balance	0
Granted	24,633,000
Vested	(16,935,000)
Forfeited	0
Nonvested restricted stock awards or restricted stock units, Ending Balance	7,698,000	0
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Beginning Balance	$ 3.88
Granted, Weighted Average Grant Date Fair Value	23.56
Vested, Weighted Average Grant Date Fair Value	19.26
Forfeited, Weighted Average Grant Date Fair Value	49.05
Nonvested restricted stock awards or restricted stock units, Weighted Average Grant Date Fair Value, Ending Balance	$ 26.74	$ 3.88

Stock-Based Compensation - Summary of Restricted Stock Activity (Parenthetical) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2020 shares
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units vested but not yet settled	15,691

Stock-Based Compensation - Summary of Cash Bonuses Paid to Vested Option Holders Included in Components of Expenses on Accompanying Consolidated Statement of Operations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonuses paid to vested option holders	$ 38,800
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonuses paid to vested option holders	0
Product development and technology
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonuses paid to vested option holders	29,189
Selling and Marketing Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonuses paid to vested option holders	6,878
General and Administrative Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash bonuses paid to vested option holders	$ 2,733

Basic and Diluted (Loss) Earnings Per Share - Schedule Computation of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Numerator:
Net income (loss)	$ (293,623)	$ 66,048	$ 43,793
Less: Accumulated dividends on convertible preferred stock			(12,984)
Less: Undistributed earnings allocated to convertible preferred stock		(23,607)	(17,014)
Net (loss) income attributable to common stockholders - basic	(293,623)	42,441	13,795
Add: Undistributed earnings reallocated to holders of common stock		304	431
Net (loss) income attributable to common stockholders - diluted	$ (293,623)	$ 42,745	$ 14,226
Denominator:
Weighted average shares - basic	274,696	226,607	111,842
Dilutive impact of stock options, restricted stock awards and restricted stock units		4,602	6,502
Weighted average shares - diluted	274,696	231,209	118,344
(Loss) earnings per share:
Basic	$ (1.07)	$ 0.19	$ 0.12
Diluted	$ (1.07)	$ 0.18	$ 0.12

Basic and Diluted (Loss) Earnings Per Share - Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	92,479	126,046	137,946
Stock Options, Restricted Stock Awards and Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	27,374	7,304	2,539

Condensed Financial Information of Parent Company - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Condensed Financial Information Of Parent Company Only Disclosure [Line Items]
Dividends received from subsidiary	$ 0	$ 0	$ 606,000,000
Minimum \| GoodRx, Inc.
Condensed Financial Information Of Parent Company Only Disclosure [Line Items]
Percentage of restricted net assets of subsidiary on consolidated net assets	25.00%

Condensed Financial Information of Parent Company - Schedule of Parent-only Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets
Total assets	$ 1,470,114	$ 386,796
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Total liabilities	758,755	737,369
Redeemable convertible preferred stock
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		737,009
Stockholders' equity (deficit)
Additional paid-in capital	2,101,773	8,788
Accumulated deficit	(1,390,453)	(1,096,830)
Total stockholders' equity (deficit)	711,359	(1,087,582)	$ (1,162,427)	$ (31,753)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	1,470,114	386,796
Common Stock
Stockholders' equity (deficit)
Common stock		460
Total stockholders' equity (deficit)		460	$ 451	$ 157
Class A and Class B Common Stock
Stockholders' equity (deficit)
Common stock	39
Total stockholders' equity (deficit)	39
GoodRx Holdings, Inc
Assets
Cash	5	110
Other asset	57	147
Investment in subsidiary, net of distributions	711,384
Total assets	711,446	257
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Investment in subsidiary, net of distributions		350,830
Other current liabilities	87
Total liabilities	87	350,830
Redeemable convertible preferred stock
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively		737,009
Stockholders' equity (deficit)
Additional paid-in capital	2,101,773	8,788
Accumulated deficit	(1,390,453)	(1,096,830)
Total stockholders' equity (deficit)	711,359	(1,087,582)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	711,446	257
GoodRx Holdings, Inc \| Common Stock
Stockholders' equity (deficit)
Common stock		$ 460
GoodRx Holdings, Inc \| Class A and Class B Common Stock
Stockholders' equity (deficit)
Common stock	$ 39

Condensed Financial Information of Parent Company - Schedule of Parent-only Balance Sheets (Parenthetical) (Details) - $ / shares	Dec. 31, 2020	Sep. 24, 2020	Dec. 31, 2019
Redeemable convertible preferred stock, par value	$ 0.006		$ 0.006
Redeemable convertible preferred stock, shares authorized	0		130,000,000
Redeemable convertible preferred stock, shares issued	0		126,046,000
Redeemable convertible preferred stock, shares outstanding	0		126,046,000
Common Stock
Common stock, par value	$ 0.002		$ 0.002
Common stock, shares authorized	0		380,000,000
Common stock, shares issued	0		229,750,000
Common stock, shares outstanding	0		229,750,000
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	2,000,000,000	0
Common stock, shares issued	63,071,000		0
Common stock, shares outstanding	63,071,000		0
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000	0
Common stock, shares issued	328,589,000		0
Common stock, shares outstanding	328,589,000		0
GoodRx Holdings, Inc
Redeemable convertible preferred stock, par value	$ 0.006		$ 0.006
Redeemable convertible preferred stock, shares authorized	0		130,000,000
Redeemable convertible preferred stock, shares issued	0		126,046,000
Redeemable convertible preferred stock, shares outstanding	0		126,046,000
GoodRx Holdings, Inc \| Common Stock
Common stock, par value	$ 0.002		$ 0.002
Common stock, shares authorized	0		380,000,000
Common stock, shares issued	0		229,750,000
Common stock, shares outstanding	0		229,750,000
GoodRx Holdings, Inc \| Common Class A
Common stock, par value	$ 0.0001		$ 0.0001
Common stock, shares authorized	2,000,000,000		0
Common stock, shares issued	63,071,000		0
Common stock, shares outstanding	63,071,000		0
GoodRx Holdings, Inc \| Common Class B
Common stock, par value	$ 0.0001		$ 0.0001
Common stock, shares authorized	1,000,000,000		0
Common stock, shares issued	328,589,000		0
Common stock, shares outstanding	328,589,000		0

Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net (loss) income	$ (293,623)	$ 66,048	$ 43,793
GoodRx Holdings, Inc
Equity in (loss) earnings of subsidiary	(293,623)	66,048	43,793
Net (loss) income	$ (293,623)	$ 66,048	$ 43,793

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Cash Flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net (loss) income	$ (293,623,000)	$ 66,048,000	$ 43,793,000
Changes in assets and liabilities:
Net cash provided by operating activities	131,341,000	83,286,000	45,253,000
Cash flows from investing activities
Distribution from subsidiary	0	0	606,000,000
Net cash used in investing activities	(91,617,000)	(37,055,000)	(3,458,000)
Cash flows from financing activities
Issuance of preferred stock, net			737,009,000
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793,000
Proceeds from private placement with a related party	100,000,000
Payments of initial public offering issuance costs	(4,937,000)
Issuance of common stock		1,623,000
Dividends paid			(1,346,355,000)
Proceeds from exercise of stock options	5,343,000	3,042,000	3,349,000
Proceeds from early exercise of stock options	667,000
Employee taxes paid related to net share settlement of equity awards	(78,714,000)
Net cash provided by (used in) financing activities	905,817,000	(54,781,000)	(24,734,000)
Net change in cash, cash equivalents and restricted cash	945,541,000	(8,550,000)	17,061,000
Cash
Beginning of year	26,050,000	34,600,000	17,539,000
End of year	971,591,000	26,050,000	34,600,000
GoodRx Holdings, Inc
Cash flows from operating activities
Net (loss) income	(293,623,000)	66,048,000	43,793,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Equity in loss (earnings) of subsidiary	293,623,000	(66,048,000)	(43,793,000)
Changes in assets and liabilities:
Other asset	90,000	(147,000)
Other current liabilities	87,000
Net cash provided by operating activities	177,000	(147,000)
Cash flows from investing activities
Distribution from subsidiary			605,997,000
Investment in subsidiary	(914,434,000)	(4,908,000)
Net cash used in investing activities	(914,434,000)	(4,908,000)	605,997,000
Cash flows from financing activities
Issuance of preferred stock, net			737,009,000
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793,000
Proceeds from private placement with a related party	100,000,000
Payments of initial public offering issuance costs	(4,937,000)
Issuance of common stock		1,623,000
Dividends paid			(1,346,355,000)
Proceeds from exercise of stock options	5,343,000	3,042,000	3,349,000
Proceeds from early exercise of stock options	667,000
Employee taxes paid related to net share settlement of equity awards	(78,714,000)
Net cash provided by (used in) financing activities	914,152,000	4,665,000	(605,997,000)
Net change in cash, cash equivalents and restricted cash	(105,000)	(390,000)
Cash
Beginning of year	110,000	500,000	500,000
End of year	$ 5,000	$ 110,000	$ 500,000

Subsequent Events - Additional Information (Details) - Restricted Stock Units ("RSUs") - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Number of shares granted			0	0
Forecast \| Board of Directors
Subsequent Event [Line Items]
Vesting period	4 years
Estimated grant date fair value	$ 22.8
Weighted-average period over which cost is expected to be recognized	4 years
Common Class A
Subsequent Event [Line Items]
Vesting period		4 years
Weighted-average period over which cost is expected to be recognized		3 years 8 months 12 days
Common Class A \| Forecast \| Board of Directors
Subsequent Event [Line Items]
Number of shares granted	500,000